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 ABSTRACT 
 
Stroke is of great medical concern worldwide, being the 6
th most common cause of adult 
disability and second leading cause of death.  Chronic Obstructive Pulmonary Disease 
(COPD) is a similarly important cause of mortality and morbidity.  The World Health 
Organisation (WHO) predictions place COPD as the third most common cause of death by 
the year 2020.  There is some pathophysiological overlap between COPD, asthma and 
bronchiectasis. 
 
Many studies exist which examine stroke incidence and mortality.  Fewer studies explore 
other outcomes or the impact of specific comorbidities on outcomes. 
 
The aim of this thesis is to determine whether COPD, asthma and bronchiectasis have a 
bearing on the survival of patients hospitalised with their first stroke in Scotland. 
 
157,639 individuals were included in the study, 44.9% of whom were male.  58.1% of all 
patients had one or more comorbidities and 6.9% had a respiratory comorbidity.  74.1% of 
all patients survived for 30 days following stroke.  58.1% survived for 1 year and 35.2% 
for 5 years.  The proportions of patients with a comorbid respiratory condition surviving 
were 71.8% at 30 days, 53.5% at 1 year and 25.9% at 5 years.  Median survival for all 
patients was 818 days.  For those with no respiratory comorbidity, median survival was 
851 days.  For patients with a respiratory condition, median survival was 501 days.  
Median survival was consistently worse for individuals with a respiratory comorbidity, 
when further examined by age and deprivation category.  The difference in survival was 
more marked in the younger age groups. 
 
A respiratory comorbidity adversely and significantly affects the outcome, in terms of 
survival, following first stroke.  The reasons for this are not entirely clear and more studies 
are needed to evaluate this effect further. 
   13 
1.  INTRODUCTION 
 
Stroke 
Stroke accounts for the 6
th most common adult disability
1, is the second highest cause of 
death worldwide
2 and the third highest cause of death in the western world
3.  Stroke 
incidence is estimated to be around 3.4 to 5.2 per 1000
3.  Most studies of stroke 
epidemiology originate from the developed world although over two thirds of strokes are 
thought to occur in developing countries
4.  It is estimated that 82 per cent of strokes are 
infarction, 15 per cent intracerebral haemorrhage and 3 per cent subarachnoid 
haemorrhage
5.   
Pathophysiology & Risk Factors 
Stroke is a disease of cerebral vasculature and can be broadly split into two categories; 
cerebral ischaemia (the most common), caused by blockage of arteries, or haemorrhage.  
Stroke results by loss of blood supply to the area of brain supplied by the vessel affected 
and an inadequacy of collateral circulation.  There are several modifiable risk factors for 
stroke.  The main ones are hypertension, cigarette smoking, raised cholesterol, diabetes 
mellitus and atrial fibrillation
6.   
Haemorrhage 
Primary intracerebral haemorrhage (PICH) occurs mainly as a consequence of 
hypertensive disease resulting in small aneurysms that rupture.  The remainder are due to 
secondary haemorrhage into an area of infarction, bleeding of vascular malformations or 
cerebral amyloid angiopathy.  Subarachnoid haemorrhages are due to berry aneurysms 
rupturing into the subarachnoid space
2. 
Ischaemia 
Ischaemia is due to vessel occlusion from either an embolic event or thrombus in 
atherosclerotic vessels.  Various clinical pictures can result depending on the site and 
extent, but is usually a catastrophic neurological event resulting in a major disability.  It 
can be further classified in several ways, but most commonly by anatomical site of the 
vessel or by the clinical syndrome produced.  The major cerebral arteries are; the anterior 
cerebral (ACA), middle cerebral (MCA) and posterior cerebral (PCA) supplying the 
hemispheres with the vertebral and basilar arteries supplying the cerebellum and brainstem.    14 
A widely used clinical classification was devised by the Oxfordshire Community Stroke 
Project
7: 
  Lacunar infarcts (LACI) are pure motor, pure sensory, sensori-motor stroke or 
ataxic hemiparesis and are predictive of small lacunar infarcts in the pons or basal 
ganglia 
  Total anterior circulation infarct (TACI) describes higher cerebral dysfunction, a 
homonymous visual field defect and ipsilateral motor and/or sensory deficit of at 
least two out of three of the areas of the face, arm and leg.  This is usually due to 
MCA infarction but may involve the ACA 
  Partial anterior circulation infarcts (PACI) have only two out of the three criteria 
from TACI 
  Posterior circulation infarcts (POCI) may have ipsilateral cranial nerve palsy plus 
contralateral motor and/or sensory deficit; bilateral motor and/or sensory deficit; 
disconjugate eye movement; ataxic hemiparesis or homonymous visual field defect 
alone 
These definitions are important in terms of prognosis.  1-year mortalities for each of the 
syndromes are 60% for TACS, 15-20% for PACS and 10% for LACS
2.  A transient 
ischaemic attack (TIA) is an ischaemic event similar to any of the stroke events described 
above, but lasting less than 24 hours. 
Diagnosis & Treatment 
Diagnosis hinges on symptoms and clinical signs compatible with stroke followed by 
confirmatory imaging, usually computed tomography (CT) head scanning.  Thrombolysis 
of strokes is the most important intervention to consider in the acute setting.  Based on 
current evidence, thrombolysis needs to be given within 3 hours of stroke onset for 
maximum benefit 
8, although there are ongoing trials examining thrombolysis outside this 
window.  The main purpose of CT scanning in the context of thrombolysis is to exclude 
haemorrhage, where thrombolysis is obviously contraindicated.  Due to the narrow 
timeframe involved and certain criteria that must be met for thrombolysis, the number of 
patients receiving this treatment is relatively small 
9.  Patients with established strokes 
should be cared for in a specialist stroke unit
10, where they can receive targeted 
rehabilitation.  Secondary prevention in the form of antiplatelet agents is normally 
commenced unless there are contraindications (PICH or SAH).  If the stroke was embolic 
due to atrial fibrillation, the patient may be anticoagulated, if suitable 
11.  Risk factors such 
as blood pressure and cholesterol should be controlled and smokers should be strongly 
encouraged to quit.     15 
 
Chronic Lower Respiratory Tract Diseases 
COPD 
Definition 
Chronic obstructive pulmonary disease (COPD) is sometimes also referred to as chronic 
obstructive airways or lung disease (COAD or COLD).  It is defined by the Global 
Initiative on COLD (GOLD) as a disease “characterised by airflow limitation that is not 
fully reversible.  The airflow limitation is usually both progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases” 
12.  COPD is 
caused mainly by smoking and is currently the sixth leading cause of death and set to rise 
to the third leading cause by 2020, according to the World Health Organisation
13. 
Pathology 
COPD involves mucociliary dysfunction and structural changes within the large and small 
airways, blood vessels and pulmonary parenchyma.  Excessive mucus secretion is 
characteristic of chronic bronchitis, part of the spectrum of COPD.  The American 
Thoracic Society defines chronic bronchitis as a cough productive of sputum on most days 
of at least 3 months of two consecutive years.  This may contribute in part to the airways 
obstruction seen in COPD, with loss of elastic recoil due to emphysema being the main 
cause.  Emphysema, also part of the spectrum of COPD, is a term used to describe the 
permanent dilatation of terminal air spaces distal to the terminal bronchioles accompanied 
by destruction of their walls.  It may be further described by its distribution within the 
acinus (the area around a terminal bronchiole) as centriacinar (emphysema close to the 
bronchiole), panacinar (throughout the whole acinus) or periacinar (distal to the 
bronchiole).  The vascular changes of COPD involve vessel wall thickening due to 
inflammatory infiltration and increased amounts of smooth muscle and collagen.  It is a 
combination of these various features that are present in different amounts in each 
individual with COPD. 
Aetiology 
The most common cause of COPD by far is tobacco smoking.  GOLD states that most 
individuals will have a 20 pack year smoking history (that is 20 cigarettes per day for 20 
years).  The pathological changes are likely the result of an inflammatory response caused 
by smoke.  Although the damage caused by cigarettes is permanent, stopping smoking will   16 
slow the progression of the disease.  Not all COPD is caused by smoking and exposure to 
passive smoking, wood smoke, other fumes and environmental pollution are thought to 
contribute.  Not all smokers develop COPD implying a degree of genetic susceptibility to 
the inflammatory damage.  α-1 antitrypsin deficiency is a rare but well-known genetic 
disorder leading to an increased risk of COPD (even in non-smokers) and there may be 
others. 
Clinical Features and Progression 
Patients usually present with progressing breathlessness, with or without wheeze.  Airway 
obstruction can be quantified by the forced expiratory volume in 1 second (FEV1) and the 
ratio of FEV1 to vital capacity (VC), which is reduced.  The degree of reduction of FEV1 
reflects increasing severity.    Physical signs vary and correlate poorly to the degree of 
disease or symptoms.  Gas trapping and emphysema cause hyperinflation of the lungs and 
flattening of the diaphragm (this may be evident on chest X-ray).  Skeletal muscle 
dysfunction and weight loss often occur and are likely caused by chronic inflammation.  
FEV1 gradually declines, more rapidly in those who continue to smoke and the patients 
more breathless, resulting in limitation of physical activity.  Chronic cough and 
exacerbations of COPD are common and frequency increases with progression of the 
disease.  Mucus and inflammation within the airways causes a worsening of the airways 
obstruction leading to an acute deterioration.  Eventually, respiratory failure may develop 
and lead to cor pulmonale.  As the patient develops respiratory failure, admission to 
hospital is usually more and more frequent.  Mortality at this stage is extremely high. 
Management 
Smoking cessation is essential to slow the progression of disease.  Airflow obstruction is 
largely fixed, so response to bronchodilators is often minimal.  There may, however, be a 
useful symptomatic benefit from even small improvements.  A combination of drugs is 
often used, involving short or long-acting β2 agonists, anticholinergics and inhaled steroid 
preparations (which have been shown to reduce the frequency of exacerbations).  Oral 
steroids are usually prescribed as a short course with or without an antibiotic during an 
exacerbation.  Methylxanthines and mucolytics may sometimes be of use.  Patients should 
receive a regular influenza and pneumococcal vaccine.  Long-term oxygen therapy is used 
for patients with chronic hypoxia to reduce cor pulmonale, pulmonary hypertension and 
polycythaemia.  Some patients benefit from procedures such as lung volume reduction 
surgery or bullectomy.  Lung transplantation may be an option depending on suitability.    17 
Pulmonary rehabilitation involving breathing exercises and physical training is of use to 
reduce breathlessness. 
 
Asthma 
Definition 
Asthma comprises chronic airways inflammation, variable (reversible) airway obstruction 
and hyper responsiveness.  There may be a coexisting atopic element, such as rhinitis, but 
not always.  The resulting clinical picture is varied
14.  Some asthmatics, including never-
smokers, may progress to a state of fixed airway obstruction similar to COPD.  Also, 
degrees of reversible obstruction may exist in COPD or bronchiectasis
15. 
Pathology 
The airway inflammation central to the disease involves multiple components, involving 
many cells including eosinophils, mast cells, neutrophils and lymphocytes (CD4+T).  
There is hypertrophy of smooth muscle and mucous glands plus epithelial damage.  
Changes in lung vasculature are also known to occur with remodelling and proliferation
16. 
Aetiology 
The cause is still currently unknown and it is likely that there are multiple factors at play.  
Environmental factors are one possibility.  Exposure to cigarette smoke in children, and 
smoking in adults have both been linked to the development of asthma
17.  Exposure to 
allergens has also been proposed as a causative factor, but the evidence for this is 
inconclusive.  Similarly, the evidence for environmental pollution causing asthma is also 
lacking
18.  The influences of diet and breast feeding may also be important, but the 
interactions are complex and again, the evidence is inconclusive
19;20. 
Clinical Features and Progression 
The disease is quite heterogeneous, but the most common symptoms are cough, shortness 
of breath, chest tightness and wheeze. The clinical course is usually that of intermittent 
exacerbations due to infection, allergic stimuli, chemical or occupational exposures
21 with 
periods of less or no symptoms in between.  Some individuals may experience a more 
chronic course with pervasive wheeze and shortness of breath whilst at the other end of the 
spectrum; cough may be the only feature.  Exacerbations may be severe enough to warrant 
hospital admission.  Extreme cases can lead to the need for invasive ventilation or death – 
so rapid and careful assessment is important.  Obvious difficulty breathing, high pulse rate,   18 
quiet or silent chest on auscultation, confusion or cyanosis are all features of severe life-
threatening asthma
22. 
Management 
Treatment of asthma depends on the severity of symptoms and the frequency of 
exacerbations.  Patients with very mild disease and infrequent symptoms may use an 
inhaled short-acting β2 agonist (such as salbutamol) alone.  If symptoms persist, then a low 
dose inhaled corticosteroid (ICS) is usually prescribed.  If the patient continues to have 
symptoms despite concordance, a long-acting β2 agonist (salmeterol or formoterol) is 
added, followed by an increase in ICS dose if still uncontrolled
23;24.  A combination inhaler 
with an ICS is often the most convenient form.  The addition of other drugs, for example, 
leukotriene receptor antagonists or theophylline may be of benefit in selected patients
25.  
Smoking cessation should be encouraged and a written asthma management plan should be 
provided
23;25. 
Bronchiectasis 
Pathology 
Bronchiectasis is defined as the permanent dilatation of bronchi.  It is usually classified 
according to radiological appearances 
26.  The dilated airways are susceptible to bacterial 
infection.  Secretions may pool in the affected airways and clearance is impaired leading to 
further colonisation with microorganisms.  This leads to cyclical infection, inflammation 
and further damage
27. 
 
Aetiology 
Bronchiectasis has many possible causes, perhaps the most widely known being cystic 
fibrosis.  It may arise as a complication after respiratory infections (bacterial pneumonia, 
viral, fungal or tuberculous infection) in the immunocompetent host or in those with 
immunodeficiency such as hypogammaglobulinaemia.  There are also other congenital 
causes along with cystic fibrosis, for example primary ciliary dyskinesia or Kartagener’s 
syndrome
26.   
Clinical Features & Diagnosis 
Bronchiectasis usually presents with a chronic productive cough, often with large volumes 
of thick sputum.  Intermittent chest pain and haemoptysis are also fairly frequent.  
Haemoptysis can result from acute infectious and may rarely be massive due to erosion   19 
into a vessel.  Varying degrees of these symptoms may be present, depending on the extent 
of disease and there may also be features of other pathology such as COPD.  High 
resolution computed tomography (HRCT) scanning is the main imaging method employed 
to visualise bronchiectasis and assess the site and extent
26;27.  Spirometry is also usually 
performed as an obstructive picture may result from the small airways inflammation 
involved.  There may also be some reversibility to inhaled bronchodilator therapy
27. 
Management 
Breathing exercises and postural drainage to help clear the purulent secretions are widely 
used, but there is little evidence of benefit
28.  Acute infections should be treated with 
antibiotics and a sample of sputum cultured.  Patients who are chronically colonised, or 
suffer repeated infections may need long-term courses of antibiotics or aerosolised 
antibiotic therapy
27.  Some patients may benefit from bronchodilator therapy and inhaled 
corticosteroids may also be of benefit in reducing inflammation although further evidence 
is needed.  Surgical resection of localised areas of bronchiectasis may be indicated where 
symptoms are severe
29. 
 
The importance of comorbidities in stroke and possible 
causative links 
There are many studies of incidence and outcome data regarding stroke but relatively few 
of these consider the impact of comorbidity on outcome.  Even when comorbidities are 
analysed, respiratory conditions are frequently overlooked.  Asthma, COPD and 
bronchiectasis are relatively common diseases of the respiratory tract with some degree of 
overlap, particularly in that they are all chronic inflammatory diseases involving 
remodelling of the lungs.  Their impact on the outcome of stroke is largely unknown.  For 
the purpose of this thesis, these three disorders are considered together as “chronic lower 
respiratory diseases”.  As the prevalence of these diseases is increasing, it is important to 
have an understanding of their relationship with stroke (both in a causative (see below) and 
a coexisting context) in terms of resource provision and identifying individuals at risk of a 
poorer outcome so that targeted interventions may be employed. 
 
The inverse relationship between respiratory function and cardiovascular disease has been 
known for some time and is independent of smoking history
30.  This association has been 
reproduced in many studies.  The independence from smoking history, age and gender 
continues to be shown in more recent studies.  Patients with COPD more often die from   20 
cardiovascular causes than respiratory failure and a greater proportion of hospital 
admissions are due to a cardiovascular rather than a respiratory cause
31. 
 
Less is known about poor respiratory function as a risk factor for stroke, but the evidence 
is growing.  Kurl et al, using VO2max (maximum consumption of oxygen) as a measure of 
cardio-respiratory fitness, found a relative risk for stroke of 3.2 for those with a VO2max of 
<25.2mL/kg per minute compared with VO2max >35.3mL/kg per minute
32.  The Renfrew 
and Paisley prospective population study looked at all mortality outcomes relative to FEV1 
after adjusting for age, smoking history, diastolic blood pressure, cholesterol, body mass 
index and social class
33.  Individuals with an FEV1 in the lowest fifth (<73% predicted) had 
a relative hazard ratio of 1.65 for stroke mortality, with a gradient of decreasing risk with a 
higher FEV1.  The Copenhagen City Heart Study showed a 30% increased risk in the 
lowest FEV1 group when compared to the group with highest  FEV1
34.  The association 
was strong for both first incident and fatal first stroke (death within 28 days). This 
relationship between FEV1 and stroke has been shown in several other studies
35;36. 
 
Vascular complications might be expected in individuals with reduced lung function 
related to smoking, such as COPD, but there is no satisfactory unifying explanation for the 
results corrected for smoking or demonstrated in never-smokers.  Although smoking no 
doubt contributes to this risk, other mechanisms must be involved.  There are several 
theories to explain why poor lung function may be a chronic risk factor for stroke, or may 
act by contributing to acute triggers for stroke. 
 
It is still not entirely clear why there is an increased vascular risk in poor lung function, 
over and above that expected from smoking or in never smokers.  Systemic inflammation 
seems the most attractive way of explaining how individuals with a primarily respiratory 
condition suffer an excess of cerebrovascular morbidity and mortality.  Higher levels of 
inflammatory markers are found in subjects with poor lung function
37;38 and inflammation 
is integral to atherosclerosis
39.  Its merit is in also providing a link to other explanations.  
Infection is associated with an increase risk of stroke
40;41 and influenza vaccination may 
well be protective
42.  There is evidence that oxidative stress occurs systemically in COPD
43 
and may play a large part in atherosclerosis
44.  Both infection and oxidative stress would 
interact with inflammation.  Further research into this area may yield an increased 
understanding of the way inflammatory conditions affect the blood vessels and may offer 
novel therapeutic avenues or screening tools for both respiratory and vascular medicine.   21 
2.  LITERATURE REVIEW 
Aims 
The aim of this review is to evaluate current literature on stroke incidence, comorbidities, 
mortalities and temporal trends with specific reference to chronic lower respiratory tract 
diseases, where possible. 
 
Method 
OVID Medline searches were undertaken using keywords “stroke”, “comorbid”, 
“mortality”, “incidence”, “epidemiology” and other relevant headings.  Lateral referencing 
of the literature from the papers obtained initially was used to increase the yield of 
pertinent studies.  
 
Studies of Stroke Epidemiology 
There is a large amount of published data from the last few decades describing stroke 
epidemiology.  There are papers from all over the globe, but the bulk of these originate in 
Western Europe or the United States.  This makes global estimates of stroke epidemiology 
difficult as most of these studies describe developed countries where, according to WHO 
estimates, only a third of global strokes occur 
4.  Study sizes vary from less than 100 to 
tens of thousands and often have differences in data collection, subject inclusion and 
presentation of results.  These differences can range from quite subtle to much bigger.  It is 
these differences that make direct comparison of the available data troublesome or not very 
valid.  Warlow and Sudlow 
45 suggested a set of criteria regarding stroke incidence study 
design.  They also concluded that very few are easily comparable and there was a lack of 
data meeting their ideal criteria covering developing countries.  Ignoring the differences to 
an extent, the studies can be broadly placed into three groups; prospective population-
based studies (OXVASC or Framingham), stroke registers (Finland) and hospital-based or 
discharge data studies (Quebec).  The more comparable studies are the prospective 
population-based studies with multiple overlapping sources of case ascertainment. 80% of 
cases should be diagnostically confirmed by CT scanning with “hot pursuit” and follow-up 
of cases
46. 
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Stroke Incidence 
The literature reviewed quote similar incidence rates for stroke.  This is unsurprising given 
that they mostly cover similar populations in terms of geography and likely ethnicity.  The 
prospective studies reviewed report incidence of stroke ranging from 94.1 – 227 per 
100,000 person years.  Stroke registers report between 85.45 and 235 per 100,000 person 
years.  The lower rates were seen in Chile, Brazil and Western European studies with 
higher rates seen in Japan, Sweden, Finland and Italy.  As stated earlier, differences in 
study design make determining whether these are real or artifact very difficult.  It is also 
important to consider that the studies cover differing time periods.  One problem 
highlighted by Warlow and Sudlow can be seen in the Minneapolis study, reporting a rate 
of 416.8 per 100,000 person years in 1980.  This was a study of hospital discharge data and 
did not strictly include first incident strokes.  It captured one stroke per person per year 
meaning that some strokes may have been an individual’s second or later stroke if an 
earlier stroke was prior to the study period.  This may be responsible for such a high figure.  
Another factor to consider is the population to which the figures are standardised.  The 
PISCIS 
47 study in Chile had one of the lower rates at 97.4 per 100,000 person years.  This 
was possibly due to case ascertainment in that strict methods to ensure non-hospitalised 
cases were captured were not employed.  The authors also present the incidence as 94.1 or 
140.1 when adjusted to World or European populations – the latter figure appearing more 
in line with the European stroke studies.  It is likely important that the mean ages in 
PISCIS (61.2 in men and 68.5 in women) were considerably lower than other studies 
(especially for males).  It is well known that stroke incidence increases with age
48, 
therefore a younger population may have a lower stroke incidence if people are dying of 
other non-stroke causes when compared to populations such as Western Europe where the 
mean age has increased over the last century.  The Rotterdam study
49 returned rates of 1.7 
per 1000 person years for men aged 55-59 and rising to 69.8 in those aged over 95.  A 
similar trend was seen in Oxfordshire Community Stroke Project
50 (OCSP), although 
presented by stroke subtype.  For instance cerebral infarction occurred at a rate of 0.1 per 
1000 per year at age less than 45 and 15.0 in those over 85.  In Auckland, Bonita et al
51 
demonstrated rates of 118 per 100000 at ages 45 to 54 and 2422 per 100000 over the age of 
85. 
 
Although many of the papers do present the data in crude form and adjusted to European 
population, this is not always the case.  They may be adjusted to local population, world 
population or others.  The Poznan 
52 incidence was adjusted to the US population of 1960 
which limits its comparability to other European studies.  The higher incidence rates in   23 
developing countries, Eastern Europe and the Nordic countries may be due to levels of 
deprivation, nutrition, pollution, lifestyle and primary prevention availability 
53.  Finland 
was known to have very high levels of cardiovascular risk factors in the seventies 
54.  The 
higher rates seen in Japan (which should be comparable with other developed countries) 
may be due to other genetic or environmental factors 
3.  
 
Nearly all the studies reviewed present sex-specific data also.  Almost universally, age-
adjusted incidence of first stroke is higher in men than in women.  Notable exceptions to 
this are the Kolkata study in India (178.01 and 117.01 per 100,000 person years in women 
and men respectively – age and sex standardised rates) and the Sicily study (185 and 123 
per 100,000 person years in women and men respectively – standardised to European 
population).  The male to female ratio of the Kolkata study was roughly equal to the census 
population of the city and distribution of the study population by age range was also 
comparable between sexes.  The authors felt the high incidence in women was real and 
reflected the high prevalence of hypertension in Indian women.  The sex ratio in the Sicily 
study was very heavily weighted towards a female population, only 41.9% of the sample 
was male.  This has also likely weighted the results towards females.  The authors do not 
comment on this difference but are aware of the limitations of such a small sample size (62 
confirmed, first-ever strokes). 
 
Temporal Trends in Stroke Incidence 
Many of the studies reviewed can give some idea of changes in stroke incidence over time 
and most conclude that there has been a reduction in incidence.  The Perth Community 
Stroke Study (PCSS)
55 reported a large change, greater in men than in women.  There was 
a decline of 25% from 1990 to 1996 and a 43% reduction in rates from 1996 to 2001.  The 
authors found that this 5.5% annual decrease corresponded to a significant parallel 
reduction in stroke risk factors over both study periods.  The Quebec study reported a 
reduction in ischaemic strokes of 32.5% in men and 25.5% in women for the last five years 
of the study.  However, there was a small increase seen in the youngest age group (< 55 
years) and a small increase in haemorrhagic strokes for both sexes.  The authors believe 
that the reason for this may lie in the increased availability and accuracy of diagnostic 
imaging in stroke, such as CT scanning, the increasing prevalence of cerebral amyloid 
angiopathy or the increased use of antithrombotics as primary and secondary prevention.  
The Minneapolis study of stroke hospitalisation found the rate to be stable through the 
study period, although the problems of interpreting this study have been previously   24 
discussed.  Dijon similarly saw a stable incidence rate despite an increase in the total 
number of strokes and an ageing population.  The authors gave the possible explanations of 
failure to control hypertension and the rising incidence of diabetes.  The three Finnish 
studies confirm a decline in stroke incidence, felt to be due to a national effort to lower risk 
factors which began as the North Karelia Project in the seventies 
54.  Two Swedish studies 
in Malmö 
56 and Lund-Orup 
57;58 did not share a decrease in stroke incidence with their 
Nordic neighbour Finland.  Both studies revealed an increase between the 1980s and 1990s.  
This trend was not continued in the 2001/2 data from Lund-Orup and it was thought that, at 
least in part, differences between the method of data capture in the two periods were 
responsible for this trend.  Malmö saw an annual increase of 3.2% in men and 2.9% in 
women.  The authors of both the Malmö and Lund-Orup studies postulated that a lack of 
adequate treatment of or an increase in risk factors, particularly hypertension and obesity, 
or a change in the ethnic diversity of the Swedish population over the study period may 
help explain the findings.  Pessah-Rasmussen et al found no evidence that increased stroke 
incidence was due to decreased mortality from myocardial infarction in the Malmö data, 
but Johansson et al thought that an increase in survivors of ischaemic heart disease may be 
a factor.  A review of population studies in China 
59 found stroke incidence to be 
unchanged overall, but there were several studies showing an increase.  Male and female 
rates were seen to increase in eight of the twelve populations with female and male rates 
decreasing in four and three populations respectively.  The authors were not certain of the 
reason for this but did conclude that none of the studies met criteria for comparability as 
suggested by Sudlow and Warlow so flaws in the data could not be discounted.   
Baseline Characteristics - Age & Sex 
As with stroke incidence, the studies reviewed tend to correlate well regarding the baseline 
characteristics of the study population.  Again, this is largely unsurprising given that most 
of the data covers predominantly white European populations.  The studies with 
substantially more women being Rochester 
60 at 41% male and the Sicilian study at 41.9 % 
male.  At the other end of the spectrum the highest male proportions were seen in Kolkata 
(55% male), PISCIS (56%), Lund-Orup (56.1%), STROMA (54.4%) and FINMONICA 
61 
(56.5%).   
 
The studies have similar mean or median ages and show the same tendency for men to be 
several years younger at the time of their first stroke.  The youngest ages are seen in Brazil 
(mean 65.1 men, 65.3 women), PISCIS (mean 61.2 men, 68.5 women), Kentucky (mean 
61 both sexes) and the Finland study of 1971-73 (mean 61.9 men, 65.2 women).  This may   25 
be due to the presence of unfavourable risk factors in the population and it is worth noting 
that the mean age in the Finland 1989-91 study rose (67.7 men, 74.6 women) as stroke 
incidence fell, presumably with the national strategies to reduce cardiovascular risk and 
hence improved survival.  The low age in the South American studies may reflect a 
younger population on the whole due to poorer survival from all causes of mortality with 
advancing age. 
Comorbid Diagnoses 
There is little data available regarding the comorbidities present in the study populations at 
the time of stroke.  Where the data does exist, it predominantly covers the well-known 
associations; hypertension, diabetes mellitus and ischaemic heart disease.  Fewer studies 
have recorded the presence of congestive heart failure and chronic respiratory diseases 
such as COPD.  Not all of the studies are strictly of first incident strokes and several 
present an analysis of a subtype of stroke only.  The studies also use different definitions 
for the comorbidities which are also sometimes self-reported, calling into question the 
accuracy.  These factors make direct comparisons of the results difficult. 
COPD/Chronic lower respiratory diseases 
COPD is the least frequently measured comorbidity, appearing in only five of the studies 
reviewed.  There is no data to see how the prevalence has changed over time, nor is there 
sex-specific data.  The stroke register of Sagrat Cor-L’Allianza Hospital, Barcelona 
recorded it as present in 5.8% of patients from the data up to 1995 
62 and in 6.8% up to 
1997 
63.  The data was concerned only with ischaemic stroke subtypes and the later study 
was of patients over 85 years although data for all ages was presented.  This figure is a 
little lower than the prevalence of COPD in Spain (9.1%) as recorded by the IBERPOC 
multicentre epidemiological study in 2000 
64.  Little can be inferred from this as comparing 
and estimating prevalence for COPD is especially difficult.  Definitions relating to FEV1 
differ and it is likely under diagnosed in many parts of the world.  The American studies 
VASt (Veterans Affairs Stroke Study) in North Carolina and KCSS (Kansas City Stroke 
Study) report rates of 15.3% and 14% respectively.  The data from BOLD (Burden of Lung 
Disease) 
65 estimates a prevalence of COPD in the United States of 2-5% based on 
Spirometry but 5-15% based on symptoms.  KCSS used self reported comorbidity, whereas 
VASt used hospital discharge coding.  In either case, the use of FEV1 to confirm the 
diagnosis is likely to be low, which may account for these studies being closer to the 
symptom-based figure from BOLD.  A small study of consecutive stroke admissions to 
Glasgow Royal Infirmary 
66 found a COPD prevalence of 10.2%.  The authors did not   26 
comment on how COPD (or other risk factors) was defined other than being identified in 
the past medical history.  The prevalence in the Scottish population is currently 1.8% 
67.  
Although it may be due to differences in definitions, the high prevalence of COPD seen in 
the Scottish and American studies when compared to the whole population could be real.  
As discussed previously in this thesis, COPD is becoming recognised as a risk factor for 
vascular diseases and a risk factor for stroke would be expected to be more prevalent in the 
study population. 
 
Ischaemic Heart Disease (IHD) 
The lowest rates of IHD are seen in ARCOS 
68 (Auckland Regional Community Stroke 
Study) and OCSP/OXVASC
69 .  In both these studies, the prevalence of IHD was relatively 
stable.  In 1981 ARCOS had a rate of 10.9% and 12% in 2003.  OXVASC had a small 
reduction in IHD; 15.6% in 1981 and 12.2% in 2004.  OXVASC also saw a (larger) 
reduction in patients with a previous myocardial infarction (MI) from 18.2% in 1981 to 
12.6% in 2004.  The mean age of the study population did not change in either study.  
OXVASC saw a statistically significant increase in treatment of hypertension and 
antiplatelet use, plus a decrease in smoking over the study period.  This is a likely 
explanation for the decrease in IHD, MI and stroke incidence.  ARCOS saw similar 
reduction in smoking prevalence but a smaller increase in treatment of hypertension.  It 
may be that under treatment of hypertension is a factor in the modest increase in IHD seen, 
or it may be that improvements in treatment led to less severe strokes.  Indeed, survival 
rates post-stroke improved in ARCOS.  It may be that an increase in survivors of stroke 
has led to an increase in the prevalence of IHD.  The highest rates of IHD were seen in 
Perth (34.7%)
55, Glasgow (35.4%)
66, Sicily (29%)
70, Poland (Polish National Stroke 
Register - PNSR) (24.6-42.4%)
71 and several of the American studies.  Given that stroke 
and heart disease share risk factors, it is unsurprising that many of the studies show a high 
prevalence and that higher rates are seen in populations with higher stroke incidence. 
 
Atrial Fibrillation (AF) 
The lowest rates of AF were seen in Framingham at 1-2% in the 1950-1977 period and 3-
5% in 1990-2004.  This is significantly lower than figures from other American studies (5-
33% in Rochester
60 and 11-16% in Portland
72, although Portland chose those aged over 65 
only).  A possible reason for this is that the Framingham cohort was composed of initially 
healthy volunteers and therefore not directly comparable with the prospective Rochester   27 
study or the Portland study which used retrospective hospital data.  The current estimated 
prevalence of AF in the general American population is 0.95% (rising to 9.0% in the over 
eighty age group)
73.  A European study in Rotterdam
74 found similar results to American 
figures with an overall prevalence of 5.5% in the general population and 17.5% over 85 
years.  The highest rates within stroke study populations were reported in the PNSR 
(10.7% for haemorrhage, 23.1% for ischaemic stroke & 30.8 for undefined stroke), 
Barcelona (27% in 1995 and 29.6% in 1997 and Dijon (22.9% in the eighties, 29% in the 
nineties and 23.1% in 2000-2004).  The other studies give rates between 10% and 20%.  
Rates in OCSP/OXVASC rose from 9.6% at the start of the study to 16.8% in the period 
2002-04.  Whether this is a real increase is not clear, but it is worth remembering that the 
incidence of stroke fell over this period.  There may have been an increased vigilance for 
AF over the period or an increased pickup of an already prevalent condition.  With 
improvements in technology and ease of recording electrocardiograms (ECG), which are 
now available in some general practices, it is possible that this is the explanation.  A 
further study in Rochester
75, specifically examining AF in incident strokes also saw an 
increase.  The prevalence of AF in cases of incident stroke was measured in the periods 
1960-69, 1970-79 and 1980-89.  It was found to be 11%, 17% and 22% respectively.  
There was a doubling of odds of AF for each decade of life.  The authors thought that the 
increase in prevalence over time could not be explained by increased use of ECGs.  
Although there was an increase over the first study decade, there was no further significant 
increase over the second or third decades.  They found an increase in all risk factors in the 
subjects, many of these comorbidities also being risk factors for AF (hypertension and 
valvular heart disease in particular) and felt this was the reason for the rise in AF 
prevalence. 
 
Congestive Cardiac Failure (CCF) 
It has been known for several decades that heart failure is a risk factor for stroke
76 and 
shares several risk factors, so its prevalence within stroke patients should not be surprising.  
The lowest comorbidity rates were seen in PISCIS, Chile (4%)
47, Barcelona (5.7%)
62;63 and 
Kansas (6%)
77.  The highest rates were recorded in the Portland study (16% in 1967-71 and 
20% in 1981-84)
72.  The remainder of the studies reviewed found rates between these 
values.  Again, differences in study design make comparisons difficult.  The 1999 National 
Health Interview Survey in the United States
78 estimated the prevalence of CCF in the 
general population (by age group) to be 0.1% (18-39 years), 1.1% (40-64 years), 3.6% (65-
74 years) and 5.5% (75-105 years).  This was self-reported data and may represent an   28 
underestimate.  The figures from the American stroke studies are a little higher; 8.7% from 
Rochester
60 (with a mean age between 67 and 80 and much higher in Portland.  Given the 
links between CCF and stroke, it may be expected that the prevalence of CCF should be 
higher in a stroke population.  The significantly higher figures from Portland could 
possibly be due to a difference in study design.  Rochester was prospective, population-
based whereas Portland chiefly used hospital data with some community sampling and 
included only subjects over 65 years old.  The prevalence in a principally hospital-based 
sample may be higher.  It is difficult to determine the cause for the apparent increase in 
CCF prevalence from 1967-1984 in the Portland study.  The Quebec study showed no 
change from 1988-2002 and a study in Minnesota
79 (in the general population) also 
showed no change from 1979-2000.  Portland may have been seeing an increase in 
prevalence due to better diagnosis (improvements in cardiac ultrasonography) or an ageing 
population with increasing comorbidity.   
 
Diabetes Mellitus 
 
Diabetes Mellitus is also a well-known vascular risk factor with a two-fold increase in the 
risk of stroke within the first five years of diagnosis when compared to non-diabetics
80.  In 
light of this, a high prevalence within a stroke population would be expected.  Interestingly, 
the United Kingdom Prospective Diabetes Study (UKPDS) discovered that it was 
treatment of co-existing risk factors (chiefly hypertension) in diabetes that would lower an 
individual’s risk of stroke
81.  Having a lower fasting plasma glucose led to a reduced risk 
of most adverse outcomes in diabetes, but not stroke
82.  The lower rates were recorded in 
Auckland
83 (ARCOS; 9% in 1981-82, 15.9% in 2002-03), Perth
55 (PCSS; 12% in 1989-90, 
19.1% in 2000-01), OCSP & OXVASC
69 (10.5% in 1981-84, 9.5% in 2002-04), 
Framingham
84 (5-7% in 1950-77, 9-12% in 1990-2004).  The highest rates were seen in 
Carolina (VASt
85; 36% in 1995-97, 29% in 1979-80 and 17% in 1970-73
86), Sicily
70 (26%), 
Kansas (KCSS
77; 23%), Barcelona
62;63 (20% in 1995, 21.4% in 1997), Chile (PISCIS
47; 
21%), Poland
71 (PNSR; 12.7% for ICH, 21.2% for ischaemic stroke and 20.5% for 
unclassified strokes).  Despite having lower prevalence of diabetes at the start of the 
studies, Framingham, Perth and Auckland all saw a rise throughout the period.  This trend 
was also seen in Dijon
87 (10.4% in 1985 to 17.5% in 2004), Quebec
88 (11-21% in 1998 and 
19-27% in 2002) and North Carolina.  Prevalence is known to increase with age, has been 
increasing over time and is expected to continue increasing as global obesity levels rise
89.  
These studies fit with this observation.  Definitions of diabetes and clinical vigilance have   29 
changed over the past few decades and there may be more people being diagnosed with 
diabetes that would have gone unnoticed in the past.  Despite this, it is likely that the 
increases seen are real given the global evidence on rising obesity and diabetes levels.  The 
high levels in the North American studies also fit with the fact that North America as of the 
year 2000 had the third highest level of diabetes in the world behind India and China
89.  
Italy was ranked ninth on this table.  OXVASC found the prevalence of diabetes to be 
stable, which is consistent with UK data over the same period (2.1% in 1995 and 2000)
90.  
However, more recent data suggests there has been a sharp rise in the prevalence of 
diabetes in the UK
91, with as much as a 50% increase in the past decade. 
Hypertension 
Hypertension is the most potent risk factor for all types of stroke
92, this having been 
demonstrated in the Framingham study
93;94.  With this knowledge, it would seem very 
likely to find a high prevalence within the stroke population.  This is indeed borne out, 
with almost all of the studies having a prevalence of over 50%.  The lowest rates are seen 
in the Portland study (24% in 1967-71, rising to 56% in 1981-84), Quebec (35-38% in 
1988 and 51-56% in 2002), Kentucky (GCNKSS
95; 44% in 1993-94 and 45% in 1999) and 
Framingham (48-56% in 1950-77 and 30-34% in 1990-2004).   A much higher value 
(72.9%) was seen in the Rochester study
60.   Framingham and Kentucky may be artificially 
low for similar reasons.  Framingham was a cohort of initially healthy volunteers and the 
Kentucky study took its comorbidity data from the whole study population including both 
stroke and non-stroke individuals.  Very high prevalence is also seen in Poland (72.1% for 
ICH, 61.8% for ischaemic stroke and 64.3% for unclassified strokes) and Buenos Aires
96 
(77.1% all ages and 82.7% in the over 80s age group).  South America and Eastern Europe 
are known to have unfavourable cardiovascular risk profiles.  The prevalence, although 
still high, was a little lower in the Western European Studies; Dijon with 65.3% in 1985 
and 64.1% in 2004, Barcelona with 53.2%, Glasgow with 55.1% and OXVASC with 
60.9% in 1981 and 45.7% in 2004.  Although Dijon saw no change in premorbid 
hypertensive history, there was a significant decrease in diastolic hypertension at stroke 
onset (53.7% in 1985 to 36.4% in 2004) with a parallel fall in smoking rates and mortality.  
In essence, this likely reflects an increase in more aggressive treatment of hypertension as 
was observed in a French study of trends in hypertension over the same time period
97.  
OXVASC saw a significant reduction in the premorbid systolic and diastolic blood 
pressure values with an increase in preventative medication (antihypertensives, antiplatelet 
and cholesterol-lowering) and decrease in smoking.  This again was felt to reflect better 
recognition and treatment of vascular risk and is a similar finding to Dijon, although   30 
recorded data are not entirely comparable.  Unlike Dijon, OXVASC did not record the 
prevalence of premorbid hypertension but the number of blood pressure measurements 
above target at presentation and the prevalence of treated hypertension.  Therefore, 
although we can say that treatment increased and systolic and diastolic values responded 
favourably, the prevalence of hypertension (whether treated, partially treated or untreated) 
may have remained static or increased over the study period. 
Stroke Mortality 
As with reporting of incidence and comorbidities, there are large differences in the 
reported case fatality or survival rates.  This may well be due to the large differences in 
study design employed but may also be due to other factors such as changes in incidence or 
health care.   
30-Day and 1-Year Mortality 
The reported 30-day survival rates follow trends in stroke incidence.  Higher survival rates 
are seen in studies from the Western world (especially American and UK-based studies).  
The lowest US figure (for all stroke types) was 67% in Portland
72 (1967-1971) and the 
highest 95% in North Carolina
86 (1979-1980).  A similarly high rate of 90.7% (females) 
and 90% (males) was seen in the Swedish Malmao
56 study.  Lower survival rates were seen 
in the Finish Numminen study
98 at 65.2%.  As discussed earlier, this likely reflects the high 
incidence of cardiovascular risk factors that was known to be present in Finland during this 
time period.  The lowest reported 30-day survival rates occur in the Moscow
99 (63%) and 
Kolkatta
100 (59.92%) studies.  Das and colleagues thought the high fatality rate in Kolkata 
likely reflected a lack of good quality medical care.  Schmidt et al offer no explanation as 
to the high mortality rate in Moscow.  Their analysis of the comorbidities present show 
high levels of diabetes, obesity, kidney disease and seizures.  A possible explanation is that 
this directly influenced either the severity of stroke or immediate complications.  Despite 
the differences seen in 30-day survival rates, 1-year rates are surprisingly similar.  
Numminen reports Finish figures as 56.6%-65.9% through the time period.  The 
Oxfordshire study reported (by subtype) between 16% and 77%, Howard (North Carolina) 
demonstrated 49% to 62% over 1970-1980 and Barker (Portland) showed 47% to 64% 
(1967-1985).  Schmidt in the Moscow study returned a rate of 48%.  Although it is difficult 
to draw specific conclusions from data that is not directly, this may be partly due to a 
survivor effect.  Countries with lower 30-day survival may represent people with a worse 
risk factor or comorbidity profile presenting with more severe strokes.  The survivors are   31 
therefore “selected” to be healthier individuals and have similar 1-year mortality to other 
countries that had more favourable 30-day mortality. 
 
Survival in Stroke Subtypes 
One of the earlier stroke studies was performed in Rochester
101 from 1955-1969.  This 
showed a survival rate of 72% at 30 days for all strokes and revealed a trend in stroke 
subtypes that has been reproduced many times since.  The 30 day survival rate for 
subarachnoid haemorrhage (SAH) was 48% and for intracranial haemorrhage (ICH) was 
only 16% compared to a rate of 81% for thrombosis or embolic strokes.  This rather dismal 
outlook for SAH is repeated in studies from before 1980.  Framingham
102 found a rate of 
18% for ICH and 54% for SAH , the North Carolina study
86 demonstrated a rate of 32% 
for ICH.  There were higher survival rates seen in the Finland study 1972-1973
98 at 59.5% 
for SAH and 26.8% for ICH.  ICH due to haemorrhagic transformation is known to be 
associated with larger infarcts.  This can lead to a rise in intracranial pressure and a poorer 
outcome
103;104.  Although it could be that haemorrhagic strokes are more severe and more 
immediately life threatening, Bamford et al
105 state that stroke as a result of haemorrhage 
is also more likely to show dense neurological signs.  This could lead to a bias in that these 
patients are more likely to be admitted to hospital and are over-represented in some of the 
studies.  These factors of course depend on the design of each individual study, but it is 
clear that all the studies agree that haemorrhagic strokes convey a poor immediate and long 
term prognosis that is likely real.  The authors of most studies agreed on the reasons behind 
high case fatalities amongst unspecified strokes.  A confirmed diagnosis in a clinically 
suspected stroke is less likely to be pursued when felt inappropriate in a moribund patient. 
 
Temporal Trends in Stroke Mortality 
In general, studies from more recent years show an improvement in survival rates from 
earlier studies (i.e. those from the 1950s to the 1970s),   the obvious exception being the 
Kolkata study.  In his review of stroke, Donnan
2 believes this is most probably due to four 
main advances in healthcare; aspirin, acute stroke units, thrombolysis and surgical 
decompression of intracerebral oedema.  Barker et al
72 found an increase in 30-day 
survival from 67% (1967) to 82% (1985).  They attributed this to a decrease in severity of 
strokes (more specifically, a decrease in the number of cases presenting with coma) and a 
decrease in hypertensive heart disease amongst the population.  Howard et al
86 had similar 
findings and conclusions in the North Carolina study.   The Finland studies by   32 
Numminen
98 also saw an improved survival rate over the study period.  As discussed 
earlier, there was a national drive to reduce adverse cardiovascular risk in Finland in the 
seventies.  Numminen also felt improved survival was due to decreased severity of 
stroke
106 (there was a reduction in the proportion of ICH), which in turn may be due to this 
effort to reduce risk factors.  Bonita et al
51 also saw evidence for a reduction in severity of 
stroke in Auckland.  The PCSS
55 saw no significant increase in survival (78.1% in 1989 
and 79.8% in 2001).  There were other changes in the population, however.  The median 
age increased with a greater proportion of over 65s and the overall incidence of stroke fell.  
There was also an increase in premorbid diabetes and it may be that this coupled with an 
older stroke population led to stable mortality despite a falling incidence.  In both the 
Malmö
56 and Oyabe
107 studies, a fall in mortality was seen that was greater for women than 
for men.  Neither study could determine whether this represented changes in medical care 
or changes in stroke severity.   
 
Cause of Death 
In the OCSP, Bamford et al
105 demonstrated that 53% of deaths within 30 days occurred 
from neurological consequences of stroke and within 72 hours of admission in over half of 
the cases.  This was most common in haemorrhagic strokes, whereas in ischaemic strokes 
51% of deaths were due to pneumonias and pulmonary emboli.  Similar figures were 
arrived at in the Moscow study by Schmidt and colleagues
99.  In the acute period, 55.4% of 
deaths were due directly to the brain lesion.  The remaining deaths were due to pneumonia 
(17.6%), pulmonary embolism (13.6%), heart failure (8.6%) and MI (2.9%).  After the first 
3 months and for the 7 years of follow up, recurrent stroke as a cause of death remained at 
a fairly constant level; 24.8% at the start and 19.4% at the end.  Pneumonia was more 
common earlier on (20.0% after the first 3 months) but reduced to 13.4% of deaths by 7 
years.  The biggest shift was seen in heart failure and MI – accounting for 25.7% of deaths 
at 3 months but rising to 50.8% by the 7 year mark.  Vernino et al
108 also found that the 
stroke itself was primarily responsible for death in around 50% of cases up to 30 days.  
From 31-365 days, pulmonary and cardiac causes were prominent each causing 
approximately 30% of deaths each.  This suggests that management of cardiovascular risk 
post stroke is very important.  The Danish MONICA study
109 found that 67.5% of patients 
with nonfatal stroke (those surviving over 27 days) went on to die of cardiovascular causes.  
The standardized mortality ratio (SMR) for post-stroke cardiovascular death was calculated 
to be four times greater than the general population.  SMR for stroke death in this period 
was 8-9 times greater than the background population although the authors postulated that   33 
this may be an over-representation.  Physicians may be more likely to record stroke as a 
cause of death in a stroke patient when a more accurate cause of death may not be 
immediately obvious.  PISCIS
47 provides data on cause of death both less than and after 30 
days from stroke onset.  Less than 30 days, the main cause of death (63% of these deaths) 
by far is neurological sequelae of stroke.  Pneumonia accounts for 21%, sepsis 4% and 
cardiac 3%.  After 30 days, cardiac deaths account for 23%, pneumonia 20%, sepsis 8% 
but 31% were recorded as “unknown” (where there was insufficient data to draw a 
conclusion).  In simpler terms, immediate deaths are due to the stroke itself and deaths in 
the 30 day survivors are due to consequences of immobility or cardiac causes.  It is for this 
reason that immediate care is focused on limiting neurological damage (thrombolysis or 
treatment of oedema).  Later care must focus on reducing the effects of immobility or 
aspiration (physiotherapy, heparin or compression stockings and speech and language 
therapy) and secondary prevention (aspirin). 
 
Factors Influencing Mortality 
Howard et al
86 demonstrated that unconsciousness was the strongest predictor of death 
with a hazard ratio (HR) of 3.04.  Diabetes had a HR of 1.28 and cardiac disease a HR of 
1.92 in the haemorrhage subgroup.  In the Portland
72 study again, coma was found to be 
the major predictor of death (1-month HR of 7.74 and 1-year HR of 5.61) with a history of 
MI of hypertensive heart disease the next strongest (1-month HR 1.75 and 1-year HR of 
1.78).  Data from the Finnish studies
98 showed that pre-stroke cardiovascular disease per se 
(with the exception of atrial fibrillation) did not prove to be a predictor of death.  Only 
those with a poor premorbid functional status (Rankin score over 2) seemed to have an 
increased odds ratio (OR) of 2.72 at 30 days.  This encompassed all patients with 
disabilities causing the Rankin score to be over 2, but included cardiac and pulmonary 
diseases.  In Quebec
88, a Charlson Index
110 of 1 gave an OR of 1.25 for death at 8-30 days 
and a score of over 1 an OR of 1.66.  Goldstein et al
85 demonstrated a 29% increase in the 
odds of death at one year for a one-point increase in the Charlson Index.  The Dijon 
study
111, however, found that previous MI (OR 1.28), hypertension (OR 1.48) or age (over 
85 – OR 5.98) were all predictors of 28-day case fatality whereas AF was not.  One study 
giving a good view of the prognostic value of premorbid conditions was performed in 
Rochester by Vernino et al
108.  The highest relative risks (RR) were seen in prior 
congestive heart failure (3.29), AF (2.47), dementia (2.32), prior MI (1.84) and angina 
(1.53).  Immediately following cerebral infarction, chest infection gave the highest RR for 
death (8.08).  The Copenhagen Stroke Study
112 found that old age (over 85) was a strong   34 
predictor of early mortality with an OR of 2.5 and death within 5 years of stroke (OR 3.9).  
The authors found a higher proportion of premorbid disability and AF plus more severe 
strokes in those over 85, which may partly account for the results.  Very little study data 
exists regarding the effects of specific comorbidities on stroke outcome, but it seems in 
general that a poor premorbid functional level is certainly a poor prognostic factor.   35 
3.  AIMS AND OBJECTIVES 
The intention of this thesis is to explore the effects that a comorbid diagnosis of COPD and 
other chronic respiratory conditions have on the survival of patients hospitalised with first 
stroke in Scotland. 
 
Objectives 
 
  To describe the baseline characteristics of individuals hospitalised with incident 
stroke in Scotland between 1986 and 2005 
  To describe the baseline characteristics of individuals hospitalised with incident 
stroke in Scotland between 1986 and 2005 where there is a coexisting diagnosis of 
COPD/Bronchiectasis/asthma 
  Compare the characteristics and survival outcomes of the two groups 
  Compare distribution of causes of death between these two groups 
  Describe age-standardised population-based mortality rates in stroke in Scotland 4.  METHODS 
 
Data Source 
The data source used for the study was taken from the Scottish Morbidity Record (SMR).  
The SMR is a very important episode-based record of data managed by the Information 
and Statistics Division (ISD), sponsored by the Scottish Executive and Department of 
Health.  It is divided into different sections based on data source and numbered 
sequentially SMR01, SMR02 and so on.  SMR01 comprises data from acute admissions 
and day-cases to Scottish hospitals.  It does not include psychiatric (SMR04) or obstetric 
(SMR02) data.  Data is recorded when a patient is discharged, changes consultant or moves 
to another hospital or department.  The record contains both clinical and non-clinical data 
such as demographic details, procedure and diagnostic codes.  These codes are taken from 
the World Health Organisation (WHO) International Classification of Diseases revisions 9 
and 10 (ICD-9 & ICD-10).  ICD-10 represented a significant expansion on the codes 
available in ICD-9 and was used in SMR data from 1996 onwards.  From January 1980, 
SMR01 data has been linked with General Register Office for Scotland (GROS) death 
registrations.  This is achieved by use of a computer probability matching algorithm which 
calculates and compares a score derived from patient identifiers (name, sex, age, date of 
birth, date of death, postcode and so on)
113.  The accuracy of SMR data is regularly 
reviewed by ISD.  Main diagnosis coding was found to be accurate in 88% of cases of a 
1.75% sample of 3 months’ data checked in 2007
114.  Although in a database of this size 
inaccuracies will inevitably occur, SMR is regarded as a very useful source of data for 
large retrospective studies.  With particular regard to stroke, Davenport et al found it to be 
satisfactory for this type of study
115. 
 
Extraction of study data 
All patients with a main diagnosis of stroke leading to admission to a Scottish hospital 
between 1986 and 2005 were identified.  Using the linkage system, deaths linked to any of 
these admissions were identified up until 31
st December 2005 (after which cases were 
right-censored).  For the purposes of this study, only a patient’s hospital episode with first 
ever stroke was counted.  All other stroke hospitalisations were excluded.  Comorbid 
conditions are determined from up to five ICD-9 or 10 codes associated with each SMR 
entry.  These diagnoses are extracted from case notes at the time of SMR data collection.    37 
These records, including clinical coding, dates of admission and demographic data were 
extracted into a separate database by the University of Glasgow Public Health unit.  In the 
separate database of stroke hospitalisations made available to me, individual records were 
anonymised using unique identifiers for each case and postcode data converted to Carstairs 
deprivation categories.   
 
Statistical analysis 
Further cleaning of the data and analysis was performed using Statistics Package for Social 
Sciences (SPSS Inc., Chicago, Illinois) version 15.  Comorbid conditions and ICD codes 
for cause of death were transformed into categorical variables.  Only the primary cause of 
death was used in the analysis.  For example, death by pneumonia secondary to stroke 
would be listed as pneumonia alone.  Each case was allocated only one cause of death.  
The date of death or censoring was used to calculate time to event from the admission date.  
The variable “respiratory comorbidity” was computed from ICD-9 and 10 codes for COPD, 
bronchiectasis and asthma.  This group was then extracted from the main data for both 
separate analysis of summary statistics, demographics, comorbidity and cause of death and 
for comparison with the remainder of the dataset (those without these conditions).  This 
group may be referred to as those with “respiratory comorbidity” rather than “COPD, 
asthma and bronchiectasis” in the remainder of this text.  Kaplan-Meier plots were 
generated to determine if there was a significant difference in survival between patients 
with or without comorbid chronic respiratory conditions.  The log rank test was used to 
confirm the statistical significance of any difference.  Crude annual incidence rates were 
calculated using the GROS
116 mid-year population estimates.  Standardisation to European 
and World population figures was undertaken using tables supplied by the University of 
Glasgow Public Health unit.  Tables and charts were created using Microsoft Office Excel 
2007 (Microsoft Corporation), with the exception of the Kaplan-Meier curves generated by 
SPSS. 
 
Ethical Considerations 
Any identifiable information from records in the SMR was removed during creation of the 
database for the study.  After the records have been linked with the GROS death certificate 
data, each one becomes a sequential case number in the new database.  This information 
cannot be directly used to identify individual patients.  Therefore there are no ethical 
concerns arising from this study and the use of the database for these purposes.   38 
5.  RESULTS 
Descriptive Statistics 
Annual incidence 
 
Year 
n (crude incidence rate per 100000 per year) 
Total  Male  Female 
1986  7639  (149.44)  3283  (133.33)  4356  (164.41) 
1987  7825  (153.46)  3441  (140.14)  4384  (165.83) 
1988  7665  (150.96)  3336  (136.48)  4329  (164.41) 
1989  7708  (151.79)  3321  (135.93)  4387  (166.49) 
1990  7785  (153.21)  3370  (137.90)  4415  (167.40) 
1991  7841  (154.25)  3472  (142.03)  4369  (165.57) 
1992  8418  (165.53)  3794  (155.16)  4624  (175.13) 
1993  8624  (169.35)  3799  (155.16)  4825  (182.49) 
1994  8575  (168.06)  3709  (151.18)  4866  (183.70) 
1995  8311  (162.84)  3744  (152.61)  4567  (172.32) 
1996  7783  (152.84)  3542  (144.75)  4241  (160.33) 
1997  8061  (158.58)  3683  (150.80)  4378  (165.77) 
1998  8272  (162.93)  3822  (156.70)  4450  (168.68) 
1999  8122  (160.14)  3704  (152.02)  4418  (167.64) 
2000  7908  (156.19)  3668  (150.83)  4240  (161.15) 
2001  7975  (157.48)  3664  (150.55)  4311  (163.89) 
2002  7679  (151.92)  3458  (142.20)  4221  (160.92) 
2003  7261  (143.57)  3368  (138.34)  3893  (148.43) 
2004  7192  (141.62)  3305  (135.10)  3887  (147.67) 
2005  6995  (137.30)  3243  (132.04)  3752  (142.19) 
Table 1 - Individuals hospitalised with 1st stroke and crude annual incidence per 100000 from 1986 to 
2005 
 
Table 1 shows the absolute numbers admitted to Scottish hospitals each year with their first 
stroke and crude annual incidence rates (AIR) per 100000.  In total, 157,639 individuals 
were admitted over the study period.  This comprises 70726 men and 86913 women.  
Women have a higher incidence of stroke than men for each year studied.  The trend is an 
initial rise in incidence in the late eighties followed by two peaks in incidence for both 
sexes – although most marked for women.  The first peak for women is the 1993-94 period 
at over 180 per 100000 followed by a decline in rate to 1996 (160.33 per 100000).  There 
is then a shallower increase in incidence to 1998 (168.68 per 100000) and finally a more 
sustained fall in the rate to 2005.  The male pattern follows a similar trend although the 
period 1992-2002 is more a plateau with a less distinct drop in 1996.  Incidence rates for   39 
males are similar to twenty years ago whilst there has been a marked reduction in 
incidence for females.  Figure 1 illustrates this graphically. 
 
Figure 1 - Incidence rates of 1st stroke in men and women 
 
Year 
European standardised  World standardised 
Males  Females  Total  Males  Females  Total 
1986  137.2  109.1  120.4  88.4  69.8  77.5 
1987  141.6  109.4  116.0  91.5  70.2  74.8 
1988  136.1  106.3  113.7  88.5  68.2  73.5 
1989  133.4  106.3  112.8  85.7  67.7  72.2 
1990  134.7  106.7  113.2  87.7  68.3  73.1 
1991  136.8  105.4  113.1  88.5  67.6  72.9 
1992  149.0  111.4  121.2  96.6  71.5  78.3 
1993  148.0  115.2  123.7  95.8  73.6  79.6 
1994  143.6  117.1  124.1  93.6  75.9  80.7 
1995  143.5  109.5  119.3  94.3  71.0  78.0 
1996  134.3  101.1  111.4  87.9  65.1  72.4 
1997  138.5  104.9  114.2  91.0  68.0  74.6 
1998  142.1  105.7  116.9  93.6  68.7  76.6 
1999  136.6  105.1  114.1  89.9  68.3  74.6 
2000  133.6  100.2  110.5  88.4  64.9  72.5 
2001  131.2  99.8  110.6  86.9  64.5  72.5 
2002  122.2  98.4  106.0  80.5  64.2  69.5 
2003  117.6  90.7  99.4  77.5  59.1  65.2 
2004  113.4  88.4  96.8  75.0  57.1  63.3 
2005  108.9  86.1  93.4  72.2  56.1  61.4 
Table 2 - AIRs standardised to European and World population 
 
Table 2 shows these figures standardised to the age distribution of the European and World 
populations.  This continues to exhibit a trend comprising a peak in incidence in the early   40 
1990s with a gradual decline in incidence towards the end of the study period.  The trend 
from the crude figures for females to have a higher incidence rate is reversed upon 
standardisation.  For both European and World standardised data, males have a much 
higher AIR than females. 
Age and sex 
 
Ages 
n (%) 
Male  Female  Total 
< 55  8992 (12.7)  7645 (8.8)  16637 (10.6) 
55 - 64  12743 (18.0)  9006 (10.4)  21749 (13.8) 
65 - 74  21638 (30.6)  20107 (23.1)  41745 (26.5) 
75 - 84  20985 (29.7)  31880 (36.7)  52865 (33.5) 
85 +  6368 (9.0)  18275 (21.0)  24643 (15.6) 
Deprivation 
quintile          
1  11575 (16.9)  14713 (17.4)  26288 (17.2) 
2  13615 (19.9)  16895 (20.0)  30510 (20.0) 
3  13073 (19.1)  16118 (19.1)  29191 (19.1) 
4  14351 (21.0)  17607 (20.9)  31958 (20.9) 
5  15800 (23.1)  19022 (22.5)  34822 (22.8) 
Table 3 - distribution of study population by age range and deprivation quintiles 
 
   Age 
   Male  Female  Total 
Mean (SD)  69 (13)  74 (13)  72 (13) 
25th Percentile  62  68  65 
75th Percentile  79  83  82 
Interpercentile range  17  15  17 
Range  0-113  0-111  0-111 
Table 4 - summary of age statistics for the population 
 
Table 3 shows how the study population is distributed amongst the defined age groups and 
Carstairs deprivation quintiles.  It should be noted that deprivation quintiles could not be 
ascertained for 4870 (or 3.09%) of the records.  Age statistics are presented in Table 4.  
The mean age for both men and women was 72 with a wide range from 0 to 111.  Females 
were found to have a higher mean age (74 compared with 69 for men).  The 25
th and 75
th 
percentiles illustrate that a quarter of patients were less than 65 years old and half the 
population was at an age in the range 65 to 82 years.  When analysed separately, this was 
found to be slightly higher for women (68 to 83) than for men (62 to 79). 
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Age group and deprivation categories 
 
  
Ages 
Carstairs 1991 deprivation quintile n (%)    
   1  2  3  4  5 
M
a
l
e
 
< 55  1218  (10.5)  1495  (11.0)  1643  (12.6)  1865  (13.0)  2395  (15.2) 
55 - 64  1818  (15.7)  2139  (15.7)  2253  (17.2)  2693  (18.8)  3406  (21.6) 
65 - 74  3274  (28.3)  4116  (30.2)  4065  (31.1)  4444  (31.0)  5065  (32.1) 
75 - 84  3901  (33.7)  4362  (32.0)  3972  (30.4)  4149  (28.9)  3942  (24.9) 
85 +  1364  (11.8)  1503  (11.0)  1140  (8.7)  1200  (8.4)  992  (6.3) 
F
e
m
a
l
e
 
< 55  1077  (7.3)  1300  (7.7)  1417  (8.8)  1628  (9.2)  2007  (10.6) 
55 - 64  1201  (8.2)  1448  (8.6)  1642  (10.2)  1904  (10.8)  2518  (13.2) 
65 - 74  2933  (19.9)  3723  (22.0)  3723  (23.1)  4296  (24.4)  4826  (25.4) 
75 - 84  5702  (38.8)  6439  (38.1)  5895  (36.6)  6399  (36.3)  6455  (33.9) 
85 +  3800  (25.8)  3985  (23.6)  3441  (21.3)  3380  (19.2)  3216  (16.9) 
Table 5 - distribution of deprivation in stroke patients by age and sex group 
 
Table 5 displays the proportions of patients within each deprivation category by sex and 
age grouping.  44.1% of men and 43.4% of women are within the two most deprived 
categories (4 and 5).  For both sexes in the age groups under 75 years, there are an 
increasing number of cases in the more deprived Carstairs quintiles.  This gradient is much 
less evident in the age group 75-84 and appears to reverse in the over 85 year-olds.  The 
pattern can be seen more clearly in Figure 2 and Figure 3. 
 
 
Figure 2 - distribution of deprivation by age group - male stroke patients 
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Figure 3 - distribution of deprivation by age group - female stroke patients 
 
Comorbid conditions 
 
 
n (%) 
Male  Female  Total 
Any  41654  (58.9)  49889  (57.4)  91543  (58.1) 
Diabetes  6928  (9.8)  7320  (8.4)  14248  (9.0) 
Cancer  5100  (7.2)  5139  (5.9)  10239  (6.5) 
Respiratory 
Disease  5412  (7.7)  5390  (6.2)  10802  (6.9) 
Heart Failure  5066  (7.2)  7035  (8.1)  12101  (7.7) 
Peripheral Vascular 
Disease  5336  (7.5)  4478  (5.2)  9814  (6.2) 
Atrial Fibrillation  7283  (10.3)  10484  (12.1)  17767  (11.3) 
Hypertension  13587  (19.2)  16472  (19.0)  30059  (19.1) 
Renal Failure  1927  (2.7)  2135  (2.5)  4062  (2.6) 
Ischaemic Heart 
Disease  13733  (19.4)  13952  (16.1)  27685  (17.6) 
Falls & Fracture  4224  (6.0)  9623  (11.1)  13847  (8.8) 
Rheumatic/Valvular 
Heart Disease  1382  (2.0)  2422  (2.8)  3804  (2.4) 
PE
* & DVT
†  1431  (2.0)  1930  (2.2)  3361  (2.1) 
Depression  963  (1.4)  1838  (2.1)  2801  (1.8) 
Dementia  1924  (2.7)  4234  (4.9)  6158  (3.9) 
Alcohol Misuse  4172  (5.9)  1277  (1.5)  5449  (3.5) 
Table 6 - distribution of comorbidities in stroke patients by sex 
 
Secondary diagnoses for the stroke patients are illustrated in Table 6.  58.1% of all patients 
had one or more comorbidity in addition to stroke.  When stratified by sex, men are found 
                                                 
* Pulmonary embolism 
† Deep venous thrombosis   43 
to have at least one additional diagnosis in 58.9% of cases and women in 57.4%.  These 
data are represented graphically in Figure 4 - distribution of comorbidities in stroke 
patients by sex 
 
 
Figure 4 - distribution of comorbidities in stroke patients by sex 
 
 
The most common conditions present were cardiovascular; prior ischaemic heart disease 
(IHD), hypertension or atrial fibrillation (AF).  Diabetes, respiratory disease, cancers and 
heart failure were next most common.  Respiratory disease was recorded as being present 
in 6.9% of the study population (7.7% of men and 6.2% of women).  Most comorbidity 
seems to occur with similar frequency in men and women apart from AF (more common in 
women), alcohol misuse (more common in men) and dementia (more common in women). 
Stroke subtype 
 
   Male  Female  Total 
SAH  3678  (5.2)  6435  (7.4)  10113  (6.4) 
ICH  6203  (8.8)  6197  (7.1)  12400  (7.9) 
CI  21392  (30.2)  22106  (25.4)  43498  (27.6) 
Other  39453  (55.8)  52175  (60.0)  91628  (58.1) 
Table 7 - proportions of stroke subtypes by sex 
 
Table 7 shows the frequencies of the various subtypes of stroke.  The most common stroke 
classification is “other” or undefined in 58.1% (55.8% of men and 60.0% of women).  This 
is followed by cerebral infarction (CI; 27.6%), intracranial haemorrhage (ICH; 7.9%) and 
then subarachnoid haemorrhage (SAH; 6.4%).  CI and “other” strokes make up 85.7% of   44 
all strokes in the study population.  The different categories of stroke seem to occur in 
similar proportions for both men and women. 
 
The proportions of stroke distribution throughout the various age groupings in males and 
females are illustrated in Table 8.  The haemorrhagic types of stroke (SAH and ICH) are 
far more common within the younger age groups.  Infarction is fairly evenly spread and the 
undefined or “other” strokes are more common in the very elderly. 
 
   Age 
group 
Stroke type n (%) 
   SAH  ICH  CI  Other 
M
a
l
e
 
< 55  2130  (23.7)  1373  (15.3)  2831  (31.5)  2658  (29.6) 
55 - 64  785  (6.2)  1369  (10.7)  4423  (34.7)  6166  (48.4) 
65 - 74  527  (2.4)  1727  (8.0)  6863  (31.7)  12521  (57.9) 
75 - 84  200  (1.0)  1385  (6.6)  5703  (27.2)  13697  (65.3) 
85 +  36  (0.6)  349  (5.5)  1572  (24.7)  4411  (69.3) 
                             
F
e
m
a
l
e
 
< 55  2962  (38.7)  910  (11.9)  1859  (24.3)  1914  (25.0) 
55 - 64  1440  (16.0)  918  (10.2)  2613  (29.0)  4035  (44.8) 
65 - 74  1232  (6.1)  1625  (8.1)  5725  (28.5)  11525  (57.3) 
75 - 84  648  (2.0)  1930  (6.1)  7870  (24.7)  21432  (67.2) 
85 +  153  (0.8)  814  (4.5)  4039  (22.1)  13269  (72.6) 
Table 8 - distribution of stroke type by age category 
 
Mortality rates 
 
Year 
All ages 
Males  Females  Total 
1995  104.71  136.25  121.09 
1996  109.68  127.02  118.69 
1997  109.81  131.20  120.92 
1998  110.58  130.09  120.72 
1999  116.60  137.85  127.64 
2000  108.35  125.50  117.26 
2001  108.39  126.63  117.87 
2002  106.79  131.68  119.71 
2003  111.15  129.29  120.56 
2004  106.04  125.87  116.32 
2005  102.85  121.12  112.31 
Table 9 - Crude annual mortality rates per 100000 
 
Table 9 shows the crude annual mortality rates from 1995 to 2005 for both sexes.  Data is 
only presented for the latter decade of the study.  As the database only includes patients   45 
with first stroke, not all deaths from stroke are recorded (meaning those who had a stroke 
before the start of the study period).  Therefore the first decade would show a false rise in 
mortality that is not likely to be a true representation of reality.  There is a rise in mortality 
from stroke for men and women until 1999.  After this, there is a trend towards gradual 
reduction in the mortality rate. 
 
Year 
European standardised  World standardised 
Males  Females  Total  Males  Females  Total 
1995  96.4  79.0  86.7  60.2  48.2  53.5 
1996  100.5  72.4  84.3  62.5  44.0  52.0 
1997  99.1  74.8  85.3  62.0  45.5  52.8 
1998  98.6  74.3  85.2  62.1  45.6  53.1 
1999  102.6  78.0  89.0  64.4  47.5  55.1 
2000  93.9  71.6  81.5  59.3  44.0  50.9 
2001  92.7  71.5  81.0  58.8  43.9  50.7 
2002  90.4  73.4  81.6  57.8  45.0  51.2 
2003  93.1  72.5  81.7  58.9  44.6  51.1 
2004  87.8  69.8  78.3  55.6  42.8  48.8 
2005  83.0  67.7  74.9  52.6  41.8  46.8 
Table 10 - Standardised annual mortality rates per 100000 
 
Table 10 shows the data standardised to European and World populations.  This continues 
to show a rise in mortality, with a plateau until a gradual reduction after 2000.  Rates are 
consistently higher in men than in women throughout the whole of the study period.   46 
Stroke patients with COPD and other chronic lower 
respiratory tract diseases 
Sex and age groups 
   Age 
   Male  Female  Total 
Mean (SD)  73 (10)  73 (12)  73 (11) 
Median  74  75  74 
25th 
Percentile  67  67  67 
75th 
Percentile  80  81  80 
Interpercentile 
Range  13  14  13 
Table 11 - summary of age statistics for patients with stroke and comorbid respiratory disease 
 
In total, 10802 stroke patients had prior COPD, asthma or bronchiectasis recorded as being 
present.  This comprises 5412 men and 5390 women.  Age statistics for the subgroup of 
stroke patients with comorbid respiratory disease are summarised in Table 11.  The mean 
age overall and for both sexes was 73.  The ages of fifty percent of all patients were within 
the range 67 to 80 (67-80 for men and 67-81 for women). 
Age group and deprivation categories 
Age 
n (%) 
Male  Female  Total 
< 55  272  (5.0)  368  (6.8)  640  (5.9) 
55 - 64  749  (13.8)  681  (12.6)  1430  (13.2) 
65 - 74  1868  (34.5)  1570  (29.1)  3438  (31.8) 
75 - 84  2001  (37.0)  1978  (36.7)  3979  (36.8) 
85 +  522  (9.6)  793  (14.7)  1315  (12.2) 
Total  5412  (100.0)  5390  (100.0)  10802  (100.0) 
Deprivation 
quintile                   
1  706  (13.3)  661  (12.4)  1367  (12.8) 
2  906  (17.0)  935  (17.6)  1841  (17.3) 
3  1048  (19.7)  995  (18.7)  2043  (19.2) 
4  1221  (22.9)  1231  (23.1)  2452  (23.0) 
5  1446  (27.1)  1497  (28.1)  2943  (27.6) 
Total  5327  (100.0)  5319  (100.0)  10646  (100.0) 
Table 12 - distribution of stroke patients with comorbid respiratory disease by sex, age and 
deprivation category   47 
The distribution for patients with respiratory comorbidity within the predefined age groups 
and Carstairs deprivation quintiles can be seen in Table 12.  Most of the patients are 
between the ages of 65 and 84.  Again, there is a gradient of an increasing proportion of the 
patients in the more deprived quintiles (4 and 5).  Over half of men and women are in 
quintiles 4 and 5.  This tendency is more marked than in the stroke patients overall.  It is 
more evident in the age groups below 85 years. 
 
  
Age 
Deprivation quintile n (%) 
   1 (least 
deprived)  2  3  4  5 
M
a
l
e
 
< 55  22  (3.1)  27  (3.0)  52  (5.0)  72  (5.9)  93  (6.4) 
55 - 64  89  (12.6)  107  (11.8)  96  (9.2)  184  (15.1)  256  (17.7) 
65 - 74  216  (30.6)  319  (35.2)  369  (35.2)  404  (33.1)  539  (37.3) 
75 - 84  301  (42.6)  355  (39.2)  424  (40.5)  438  (35.9)  455  (31.5) 
85 +  78  (11.0)  98  (10.8)  107  (10.2)  123  (10.1)  103  (7.1) 
F
e
m
a
l
e
 
< 55  29  (4.4)  44  (4.7)  64  (6.4)  85  (6.9)  140  (9.4) 
55 - 64  72  (10.9)  94  (10.1)  105  (10.6)  149  (12.1)  253  (16.9) 
65 - 74  152  (23.0)  257  (27.5)  296  (29.7)  383  (31.1)  465  (31.1) 
75 - 84  267  (40.4)  379  (40.5)  371  (37.3)  458  (37.2)  473  (31.6) 
85 +  141  (21.3)  161  (17.2)  159  (16.0)  156  (12.7)  166  (11.1) 
Table 13 - distribution of age groups by deprivation category - patients with stroke and comorbid 
respiratory disease 
 
Table 13 breaks these data down by age groups and sex.  There is a strong tendency for the 
age groups under 65 to be in the more deprived quintiles.  The reverse is also true, in that 
older age categories are more frequently within the least deprived quintiles.  The difference 
in proportions in least and most deprived areas is more marked for females. 
   48 
 
Figure 5 - deprivation within age groups - males with stroke and respiratory comorbidity 
 
 
 
Figure 6 - deprivation within age group - females with stroke and respiratory comorbidity 
Comorbid conditions 
8302 of the 10802 patients with prior respiratory disease had at least one other comorbidity.  
This includes 4152 men and 4150 women.  The proportions of comorbidities present in the 
cohort of stroke patients with respiratory disease can be seen in Table 14 and graphically in 
Figure 7.  As in the entire study population, IHD and hypertension are the two most 
commonly occurring conditions.  Overall, there is a much higher level of other 
comorbidities present in this subgroup with prior respiratory disease.  Notably, heart failure   49 
is over twice as common in the respiratory disease cohort and AF, IHD and peripheral 
vascular disease (PVD) are almost twice as common.   
 
Figure 7 - other conditions in stroke patients with prior respiratory comorbidity 
 
   Male  Female  Total 
Diabetes  623  (11.5)  711  (13.2)  1334  (12.3) 
Cancer  591  (10.9)  421  (7.8)  1012  (9.4) 
Heart Failure  1003  (18.5)  1081  (20.1)  2084  (19.3) 
Peripheral 
Vascular Disease  723  (13.6)  481  (8.9)  1204  (11.1) 
Atrial Fibrillation  928  (17.1)  979  (18.1)  1907  (17.7) 
Essential 
Hypertension  1281  (23.7)  1520  (28.2)  2801  (25.9) 
Renal Failure  259  (4.8)  245  (4.5)  504  (4.7) 
Ischaemic Heart 
Disease  1945  (35.9)  1744  (32.4)  3689  (34.2) 
Rheumatic/Valvular 
Heart Disease  155  (2.9)  256  (4.7)  411  (3.8) 
Pulmonary 
Embolism & DVT  171  (3.2)  234  (4.3)  405  (3.7) 
Depression  140  (2.6)  224  (4.2)  364  (3.4) 
Dementia  229  (4.2)  301  (5.6)  530  (4.9) 
Falls & Fracture  519  (9.6)  765  (14.2)  1284  (11.9) 
Alcohol Misuse  560  (10.3)  172  (3.3)  732  (6.8) 
Table 14 - distribution of other conditions amongst stroke patients with respiratory comorbidity Stroke subtype 
The distribution of stroke subtypes by sex can be seen in Table 15.  The proportion of SAH 
in these patients compared to all stroke patients is smaller.  The remaining stroke 
categories are in similar proportions between the whole study population and this cohort.  
The undefined or “other” strokes are the most common; 57.1% in men, 56.0% in women 
and 56.5% over all.  Cerebral infarction is the next most common; 33.5% of men, 32.9% of 
women and 56.5% altogether.  CI and “other” strokes account for 89.7% of all strokes in 
individuals with prior respiratory disease. 
 
   Male  Female  Total 
SAH  111  (2.1)  247  (4.6)  358  (3.3) 
ICH  400  (7.4)  351  (6.5)  751  (7.0) 
CI  1812  (33.5)  1774  (32.9)  3586  (33.2) 
Other  3089  (57.1)  3018  (56.0)  6107  (56.5) 
Table 15 - distribution of stroke subtype in patients with respiratory comorbidity 
 
In Table 16, the distribution of stroke subtype amongst the age categories can be seen.  As 
in the whole stroke study population, the haemorrhagic stroke types are more common in 
the younger age groups.  However, this is to a lesser extent in the respiratory comorbidity 
subgroup in comparison to the entire study population.  Cerebral infarction is more 
common across all age groups than was seen in the parent population.  The undefined or 
“other” category of stroke is slightly more common also, but only in the two youngest age 
groups. 
 
   Age 
group 
Stroke type n (%) 
   SAH  ICH  CI  Other 
M
a
l
e
 
< 55  33  (12.1)  34  (12.5)  109  (40.1)  96  (35.3) 
55 - 64  39  (5.2)  72  (9.6)  260  (34.7)  378  (50.5) 
65 - 74  23  (1.2)  141  (7.5)  668  (35.8)  1036  (55.5) 
75 - 84  12  (0.6)  118  (5.9)  631  (31.5)  1240  (62.0) 
85 +  4  (0.8)  35  (6.7)  144  (27.6)  339  (64.9) 
                             
F
e
m
a
l
e
 
< 55  82  (20.6)  39  (9.8)  133  (33.4)  144  (36.2) 
55 - 64  61  (9.0)  52  (7.6)  240  (35.2)  328  (48.2) 
65 - 74  69  (4.4)  111  (7.1)  581  (37.0)  809  (51.5) 
75 - 84  29  (1.5)  117  (5.9)  604  (30.5)  1228  (62.1) 
85 +  6  (0.8)  32  (4.0)  216  (27.2)  539  (68.0) 
Table 16 - distribution of stroke subtype by age groups in patients with respiratory comorbidity Survival 
Stroke patients 
Out of the 157639 stroke patients, only 41860 (26.6%) were still alive at the end of the 
study period.  The overall survival rate to 30 days was 74.1% (95% CI
‡ 74.0-74.2), to 1 
year was 58.1% (95% CI 58.0-58.2) and to 5 years was 35.2% (95% CI 35.1-35.3).  A 
breakdown of survival data by age group and deprivation quintile is provided in Table 17. 
 
      Survival (% (95% CI)) 
      30 days  1 year  5 years 
A
g
e
 
c
a
t
e
g
o
r
y
  All  74.1 (74.0 to 74.2)  58.1 (58.0 to 58.2)  35.2 (35.1 to 35.3) 
< 55  83.5 (83.2 to 83.8)  80.2 (79.9 to 80.5)  72.2 (71.8 to 72.5) 
55 - 64  81.6 (81.3 to 81.9)  73.8 (73.5 to 74.1)  57.1 (56.7 to 57.4) 
65 - 74  76.8 (76.6 to 77.0)  63.5 (63.2 to 63.7)  39.9 (39.6 to 40.1) 
75 - 84  70.7 (70.5 to 70.9)  50.6 (50.4 to 50.9)  23.6 (23.4 to 23.8) 
85 +  64.0 (63.7 to 64.3)  36.6 (36.3 to 36.9)  11.2 (11.0 to 11.4) 
D
e
p
r
i
v
a
t
i
o
n
 
q
u
i
n
t
i
l
e
 
1  74.5 (74.3 to 74.8)  58.1 (57.8 to 58.4)  34.9 (34.6 to 35.2) 
2  73.5 (73.2 to 73.7)  57.0 (56.7 to 57.3)  33.9 (33.7 to 34.2) 
3  73.6 (73.3 to 73.8)  57.7 (57.4 to 58.0)  34.6 (34.3 to 34.9) 
4  73.9 (73.6 to 74.1)  57.8 (57.5 to 58.0)  35.1 (34.8 to 35.3) 
5  75.4 (75.2 to 75.6)  59.4 (59.2 to 59.7)  35.8 (35.6 to 36.1) 
Table 17 - unadjusted survival of stroke patients by age and deprivation 
 
There exists a decreasing gradient of survival with increasing age both in the short and 
long term.  This is especially evident at 5 years.  At this point, only 11.2% (95% CI 11.0-
11.4) of those aged over 85 years were still alive compared with 72.2% (95% CI 71.8-72.5) 
of those aged under 55 years.  Survival rates at each time point are very similar for the 
deprivation quintiles and there is little difference in survival between the most and least 
deprived categories. 
 
The 30 day, 1 and 5 year survival data is further stratified by gender in Table 18.  Males 
have a higher survival rate than females in most age groups and deprivation categories, 
though this tendency is only slight and is less evident with increasing age.  Again, although 
the pattern for higher survival in males than females is still evident, there is little variation 
in survival from the more deprived to the less deprived categories. 
The survival data for each of the comorbidities is available in Table 19.  At 30 days there is 
only a slight difference in survival between those with no comorbidity and those with one 
or more.  This difference increases at 1 year and further still at 5 years where there is an 
                                                 
‡ CI – Confidence interval   52 
almost 10% higher survival rate for men and women.  For 30 days, 1 year and 5 year 
follow up; survival is highest amongst those men and women with prior hypertension.  
This is followed (in decreasing order of survival) by depression, diabetes mellitus and 
alcohol misuse.   Respiratory disease, heart failure, renal failure and dementia are 
consistently the comorbidities associated with worse survival at 30 days, 1 and 5 years.   
       Survival (% (95% CI)) 
      30 days  1 year  5 years 
      Male  Female  Male  Female  Male  Female 
A
g
e
 
c
a
t
e
g
o
r
y
 
All  77.0 (76.8 to 77.2)  71.8 (71.6 to 71.9)  62.1 (61.9 to 62.3)  54.9 (54.7 to 55.0)  38.6 (38.5 to 38.8)  32.5 (32.3 to 32.6) 
< 55  84.7 (84.4 to 85.1)  82.1 (81.7 to 82.5)  81.3 (80.8 to 81.7)  78.9 (78.5 to 79.4)  71.9 (71.4 to 72.4)  72.5 (72.0 to 73.1) 
55 - 64  83.5 (83.2 to 83.9)  78.9 (78.4 to 79.3)  75.8 (75.4 to 76.1)  71.1 (70.7 to 71.6)  57.7 (57.3 to 58.2)  56.1 (55.5 to 56.6) 
65 - 74  78.5 (78.2 to 78.8)  75.0 (74.7 to 75.3)  64.8 (64.5 to 65.1)  62.0 (61.7 to 62.3)  39.7 (39.3 to 40.0)  40.1 (39.8 to 40.5) 
75 - 84  71.9 (71.6 to 72.2)  69.9 (69.6 to 70.1)  50.7 (50.4 to 51.0)  50.6 (50.3 to 50.9)  22.1 (21.8 to 22.4)  24.5 (24.3 to 24.8) 
85 +  64.8 (64.2 to 65.4)  63.7 (63.4 to 64.1)  36.5 (35.9 to 37.1)  36.7 (36.3 to 37.0)  10.0 (9.6 to 10.4)  11.6 (11.4 to 11.8) 
D
e
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  1  77.0 (76.6 to 77.4)  72.6 (72.2 to 72.9)  62.0 (61.6 to 62.5)  55.0 (54.6 to 55.4)  38.5 (38.1 to 39.0)  32.2  (31.8 to 32.5) 
2  76.1 (75.8 to 76.5)  71.3 (71.0 to 71.7)  60.8 (60.3 to 61.2)  54.0 (53.6 to 54.4)  37.1 (36.7 to 37.5)  31.4 (31.1 to 31.8) 
3  76.7 (76.3 to 77.0)  71.0 (70.7 to 71.4)  61.7 (61.3 to 62.1)  54.5 (54.1 to 54.9)  38.2 (37.7 to 38.6)  31.8 (31.4 to 32.2) 
4  77.0 (76.6 to 77.3)  71.4 (71.1 to 71.7)  61.7 (61.3 to 62.1)  54.5 (54.2 to 54.9)  38.5 (38.0 to 38.9)  32.3 (31.9 to 32.7) 
5  78.4 (78.0 to 78.7)  72.9 (72.6 to 73.2)  63.4 (63.0 to 63.8)  56.2 (55.8 to 56.5)  38.7 (38.3 to 39.1)  33.5 (33.2 to 33.9) 
Table 18 - unadjusted survival of stroke patients by age, sex and deprivation 
 The difference in survival between the comorbidity associated with the highest rate and 
that associated with the lowest rate becomes more marked at 1 year and even more so at 5 
years.  For instance, survival in men with stroke and hypertension at 1 year is 73.1% (95% 
CI 72.7-73.5) compared with the lowest survival rate in men with stroke and renal failure 
at 41.3% (95% CI 40.1-42.4).  A similar comparison for men at 5 years is the highest rate 
of survival in hypertension; 48.3% (95% CI 47.9-48.8) versus the lowest survival in 
dementia; 15.1% (95% CI 14.3-16.0).  This can be seen graphically in Figure 8, Figure 9 
and Figure 10. 
 
 
Figure 8 - 30 day stroke survival rates for each comorbidity 
 
 
 
Figure 9 - 1 year stroke survival rates for each comorbidity  
   Survival (% (95% CI)) 
   30 days  1 year  5 years 
   Male  Female  Male  Female  Male  Female 
None  76.0 (75.7 to 76.2)  70.7 (70.5 to 70.9)  63.5 (63.2 to 63.8)  57.3 (57.0 to 57.5)  43.5 (43.2 to 43.8)  38.0 (37.7 to 38.3) 
Any  77.7 (77.5 to 77.9)  72.5 (72.3 to 72.7)  61.1 (60.9 to 61.3)  53.1 (52.9 to 53.3)  35.1 (34.9 to 35.4)  28.3 (28.1 to 28.5) 
Diabetes  80.8 (80.3 to 81.3)  76.6 (76.1 to 77.1)  63.9 (63.3 to 64.5)  57.1 (56.6 to 57.7)  35.9 (35.3 to 36.5)  30.0 (29.4 to 30.5) 
Cancer  69.0 (68.3 to 69.6)  66.2 (65.5 to 66.8)  43.1 (42.4 to 43.8)  40.5 (39.8 to 41.2)  18.2 (17.7 to 18.8)  18.3 (17.7 to 18.8) 
Respiratory  73.7 (73.1 to 74.3)  69.8 (69.2 to 70.4)  54.3 (53.6 to 55.0)  52.6 (51.9 to 53.3)  25.4 (24.8 to 26.0)  26.5 (25.9 to 27.1) 
Heart Failure  66.3 (65.6 to 67.0)  62.2 (61.6 to 62.7)  43.6 (42.9 to 44.3)  36.5 (35.9 to 37.1)  18.1 (17.6 to 18.7)  13.1 (12.7 to 13.5) 
PVD  74.9 (74.3 to 75.5)  68.6 (67.9 to 69.3)  55.5 (54.8 to 56.2)  47.4 (46.7 to 48.2)  28.0 (27.4 to 28.6)  23.7 (23.0 to 24.3) 
AF  77.4 (76.9 to 77.9)  71.2 (70.8 to 71.7)  58.9 (58.4 to 59.5)  49.5 (49.0 to 50.0)  31.1 (30.6 to 31.7)  23.7 (23.3 to 24.1) 
Essential Hypertension  85.0 (84.7 to 85.3)  79.6 (79.3 to 79.9)  73.1 (72.7 to 73.5)  64.5 (64.2 to 64.9)  48.3 (47.9 to 48.8)  39.8 (39.4 to 40.2) 
Renal Failure  65.8 (64.7 to 66.9)  60.6 (59.6 to 61.7)  41.3 (40.1 to 42.4)  33.4 (32.4 to 34.4)  19.3 (18.3 to 20.2)  13.6 (12.9 to 14.4) 
Ischaemic Heart Disease  76.5 (76.2 to 76.9)  70.0 (69.7 to 70.4)  59.1 (58.7 to 59.6)  49.9 (49.5 to 50.3)  32.7 (32.3 to 33.1)  25.5 (25.1 to 25.9) 
Valvular Heart Disease  76.9 (75.7 to 78.0)  74.0 (73.1 to 74.9)  59.3 (58.0 to 60.7)  54.6 (53.6 to 55.6)  32.8 (31.4 to 34.1)  29.5 (28.6 to 30.5) 
PE & DVT  74.0 (72.8 to 75.2)  71.1 (70.1 to 72.2)  57.2 (55.9 to 58.6)  49.0 (47.8 to 50.1)  31.5 (30.2 to 32.8)  27.6 (26.5 to 28.6) 
Depression  83.5 (82.3 to 84.7)  80.4 (79.5 to 81.3)  64.6 (63.1 to 66.2)  60.3 (59.2 to 61.5)  33.6 (32.0 to 35.2)  32.7 (31.6 to 33.9) 
Dementia  75.4 (74.5 to 76.4)  72.1 (71.4 to 72.8)  45.2 (44.1 to 46.3)  42.1 (41.3 to 42.8)  15.1 (14.3 to 16.0)  12.9 (12.4 to 13.4) 
Alcohol Misuse  80.1 (79.5 to 80.7)  75.3 (74.1 to 76.5)  66.7 (65.9 to 67.4)  61.2 (59.8 to 62.6)  40.1 (39.3 to 40.9)  38.8 (37.3 to 40.2) 
Table 19 - unadjusted survival by prior comorbidity and sex  
Figure 10 - 5 year stroke survival rates for each comorbidity 
   Survival (% (95% CI)) 
   30 days  1 year  5 years 
   Male  Female  Male  Female  Male  Female 
SAH  72.7 (72.0 to 73.5)  69.9 (69.3 to 70.5)  68.6 (67.9 to 69.4)  64.2 (63.6 to 64.8)  60.4 (59.6 to 61.3)  56.1 (55.4 to 56.7) 
ICH  59.5 (58.9 to 60.1)  53.9 (53.3 to 54.6)  49.8 (49.1 to 50.4)  42.6 (41.9 to 43.2)  33.6 (33.0 to 34.2)  27.0 (26.5 to 27.6) 
CI  88.7 (88.5 to 88.9)  85.4 (85.2 to 85.7)  75.3 (75.0 to 75.6)  68.8 (68.5 to 69.1)  49.2 (48.8 to 49.6)  42.8 (42.5 to 43.2) 
Other  73.8 (73.6 to 74.0)  68.3 (68.1 to 68.5)  56.4 (56.2 to 56.7)  49.4 (49.2 to 49.6)  32.3 (32.0 to 32.5)  26.3 (26.1 to 26.5) 
Table 20 - unadjusted survival by stroke subtype and sex 
 
Table 20 presents an analysis of survival within each of the stroke subtypes.  At 30 days 
and 1 year, CI is associated with the most favourable survival rate and ICH with the least 
favourable rates.  However, survival is highest in those patients with SAH at 5 years and 
lowest in those with “other” stroke. 
Stroke patients with COPD and other chronic lower respiratory 
tract diseases 
      Survival (% (95% CI)) 
      30 days  1 year  5 years 
  All  71.8 (71.3 to 72.2)  53.5 (53.0 to 54.0)  25.9 (25.5 to 26.4) 
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  < 55  84.5 (83.1 to 85.9)  79.1 (77.5 to 80.8)  65.7 (63.7 to 67.8) 
55 - 64  80.2 (79.1 to 81.2)  70.6 (69.4 to 71.8)  47.7 (46.3 to 49.1) 
65 - 74  74.4 (73.6 to 75.1)  58.0 (57.2 to 58.9)  28.5 (27.7 to 29.3) 
75 - 84  67.6 (66.9 to 68.4)  46.3 (45.5 to 47.1)  16.6 (16.0 to 17.2) 
85 +  62.2 (60.8 to 63.5)  33.1 (31.8 to 34.4)  8.4 (7.6 to 9.1) 
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1  72.6 (71.4 to 73.8)  54.3 (52.9 to 55.7)  25.5 (24.3 to 26.7) 
2  70.6 (69.6 to 71.7)  50.5 (49.4 to 51.7)  24.5 (23.4 to 25.5) 
3  70.3 (69.3 to 71.3)  52.2 (51.1 to 53.3)  25.7 (24.7 to 26.7) 
4  72.0 (71.1 to 72.9)  53.4 (52.4 to 54.4)  26.1 (25.2 to 27.1) 
5  73.0 (72.2 to 73.9)  56.0 (55.1 to 56.9)  26.7 (25.8 to 27.5) 
Table 21 - unadjusted survival by age and deprivation - stroke patients with respiratory comorbidity 
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Corresponding survival data at 30 days, 1 year and 5 years for the stroke patients with 
respiratory comorbidity are presented in Table 21.  Overall survival for both sexes was 
71.8% (95% CI 71.3 to 72.2) at 30 days, 53.5 (95% CI 53.0 to 54.0) at 1 year and 25.9 
(95% CI 25.5 to 26.4) at 5 years.  As with the parent population, survival is lower with 
each older age category.  The survival rates reduce strikingly at 1 year and further still at 5 
years and are consistently lower than those for the whole population.  The confidence 
intervals do not cross those of the parent population in any of the age categories apart from 
less than 55 years at 30 days and one year.  Otherwise, survival is significantly lower for 
all the other ages at each time point.  There is a suggestion of decreasing survival with the 
more deprived deprivation quintiles, but again the confidence intervals overlap widely, 
making this pattern non-significant. 
 
Table 22 presents the data from Table 21 divided into male and female categories.  Males 
have a higher survival than females at most points (in terms of age, deprivation quintile 
and at each time point).  This is less so at 5 years where females appear to have a survival 
advantage in some categories (50.3 (95% CI 48.3 to 52.4) for females age 55-64 compared 
with 45.5 (95% CI 43.6 to 47.4) for males).  Females also have higher survival at ages 75-
84 and over 85 years, with non-overlapping confidence intervals.  As with the data for both 
sexes, when survival and deprivation is analysed by sex, there is no gradient of survival 
across the quintiles. 
 
In Table 23, the survival data is tabulated by sex and stroke type as before.  There is no 
difference between male and female survival for SAH at any endpoint.  For ICH, only at 
30 days do men have a higher survival rate with there being no significant sex difference at 
1 or 5 years.  Males have a greater survival rate than females with CI at 30 days and 1 year, 
but not at 5 years where the confidence intervals overlap and there is no significant 
difference.  Females have higher survival rates than males for “other” strokes at 5 years, 
but at 30 days and 1 year, male survival is greater.  Both sexes with chronic respiratory 
diseases have a poorer survival for all strokes at 30 days, 1 and 5 years when compared 
with the whole population.  Survival from ICH is poorest at 30 days and 1 year, with 
“other” strokes being least survivable at 5 years by both sexes.  The best prognosis is from 
CI at 30 days and 1 year, with SAH having the highest proportion of both sexes surviving 
at 5 years.  The pattern here for those with chronic respiratory comorbidity is similar to 
that of the whole population.  
      Survival (% (95% CI)) 
      30 days  1 year  5 years 
      Male  Female  Male  Female  Male  Female 
  All  73.7 (73.1 to 74.3)  69.8 (69.2 to 70.4)  54.3 (53.6 to 55.0)  52.6 (51.9 to 53.3)  25.4 (24.8 to 26.0)  26.5 (25.9 to 27.1) 
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  < 55  86.3 (84.3 to 88.4)  83.1 (81.2 to 85.1)  80.4 (77.9 to 82.8)  78.2 (76.0 to 80.4)  65.9 (62.8 to 69.0)  65.6 (62.9 to 68.3) 
55 - 64  79.9 (78.5 to 81.4)  80.4 (78.9 to 82.0)  70.0 (68.3 to 71.7)  71.3 (69.5 to 73.0)  45.5 (43.6 to 47.4)  50.3 (48.3 to 52.4) 
65 - 74  76.2 (75.2 to 77.2)  72.2 (71.1 to 73.3)  58.7 (57.6 to 59.9)  57.2 (55.9 to 58.4)  28.6 (27.5 to 29.7)  28.4 (27.2 to 29.6) 
75 - 84  70.0 (69.0 to 71.1)  65.2 (64.2 to 66.3)  46.6 (45.5 to 47.7)  45.9 (44.8 to 47.0)  15.1 (14.3 to 16.0)  18.1 (17.2 to 19.0) 
85 +  63.8 (61.7 to 65.9)  61.1 (59.4 to 62.8)  32.9 (30.9 to 35.0)  33.2 (31.6 to 34.9)  7.3 (6.1 to 8.4)  9.1 (8.1 to 10.1) 
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1  74.2 (72.5 to 75.8)  70.9 (69.1 to 72.7)  54.7 (52.8 to 56.6)  53.9 (52.0 to 55.9)  24.9 (23.3 to 26.6)  26.1 (24.3 to 27.9) 
2  73.6 (72.1 to 75.0)  67.8 (66.3 to 69.3)  52.9 (51.2 to 54.5)  48.3 (46.6 to 49.9)  24.6 (23.1 to 26.1)  24.4 (22.9 to 25.8) 
3  71.5 (70.1 to 72.9)  69.0 (67.5 to 70.5)  52.1 (50.5 to 53.6)  52.4 (50.8 to 53.9)  24.0 (22.6 to 25.4)  27.5 (26.1 to 29.0) 
4  73.8 (72.5 to 75.0)  70.3 (69.0 to 71.6)  53.7 (52.2 to 55.1)  53.1 (51.7 to 54.6)  26.2 (24.9 to 27.5)  26.1 (24.8 to 27.4) 
5  75.8 (74.6 to 76.9)  70.4 (69.2 to 71.6)  57.6 (56.3 to 58.9)  54.5 (53.2 to 55.8)  26.0 (24.8 to 27.2)  27.3 (26.1 to 28.5) 
Table 22 - unadjusted survival by sex, age and deprivation - stroke patients with respiratory comorbidity 
   Survival (% (95% CI)) 
   30 days  1 year  5 years 
   Male  Female  Male  Female  Male  Female 
SAH  66.7 (62.2 to 71.1)  67.9 (64.9 to 70.9)  59.4 (54.7 to 64.2)  61.0 (57.8 to 64.2)  47.4 (42.4 to 52.5)  44.7 (41.3 to 48.1) 
ICH  57.9 (55.4 to 60.4)  54.7 (52.0 to 57.4)  43.8 (41.3 to 46.3)  41.6 (38.9 to 44.3)  21.1 (19.0 to 23.2)  22.2 (19.9 to 24.5) 
CI  85.6 (84.7 to 86.4)  83.3 (82.4 to 84.2)  68.0 (66.9 to 69.1)  66.4 (65.2 to 67.5)  35.6 (34.4 to 36.8)  35.1 (33.9 to 36.3) 
Other  69.1 (68.3 to 70.0)  63.8 (62.9 to 64.7)  47.7 (46.8 to 48.6)  45.3 (44.3 to 46.2)  19.7 (18.9 to 20.4)  20.9 (20.2 to 21.7) 
Table 23 - unadjusted survival by sex and stroke subtype - patients with respiratory comorbidity Kaplan Meier (KM) survival curves 
Survival – all patients with and without respiratory disease 
 
Figure 11 - Kaplan-Meier (KM) plot of survival of stroke patients with and without respiratory 
comorbidity 
Figure 11 is a KM plot for all patients followed up to 7000 days.  The two curves compare 
survival for those with respiratory disease to those without respiratory disease.  Early on, 
there is a definite divergence in that patients with respiratory comorbidity clearly have a 
poorer survival at each time point.  The median survival (see Table 24) for those with a 
stroke and no respiratory comorbidity was 851 days (95% CI 835 to 867) and for those 
with respiratory comorbidity was 501 days (95% CI 466 to 536).  This was statistically 
significant by the log rank test (p-value <0.001).  Figure 12 and Figure 13 show the KM 
plots for each sex.  The difference in survival between respiratory comorbidity and no 
respiratory comorbidity is greater for males than for females, and overall survival in 
females is worse than males.  Median survival for all males was 1051 days (95% CI 1027   60 
to 1075) and for females was 630 days (95% CI 611 to 649).  Comparing no prior 
respiratory disease to respiratory disease respectively; for males survival was 1119 days 
(95% CI 1093 to 1145) without and 517 days (95% CI 471 to 563) with respiratory 
comorbidity and for females 644 days (95% CI 624 to 664) without and 490 days (95% CI 
436 to 544) with respiratory disease. 
KM plots by sex 
Figure 12 plots the survival of the two groups studied for females and Figure 13 shows the 
same data for males.  
KM plots by age group 
Figure 14 shows the KM plot for respiratory comorbidity against no prior respiratory 
comorbidity for the under 55 age group, Figure 15 for the group 55 to 64, Figure 16 for the 
65 to 74 group, Figure 17 for ages 75 to 84 and Figure 18 for those aged 85 and over.  A 
significant difference (p-value <0.001) is seen between the two groups at each range of age.  
This difference diminishes with increasing age group, but is still significant. 
KM plots by age group 
Figure 14 shows the KM plot for respiratory comorbidity against no prior respiratory 
comorbidity for the under 55 age group, Figure 15 for the group 55 to 64, Figure 16 for the 
65 to 74 group, Figure 17 for ages 75 to 84 and Figure 18 for those aged 85 and over.  A 
significant difference (p-value <0.001) is seen between the two groups at each range of age.  
This difference diminishes with increasing age group, but is still significant. 
KM plots by deprivation category 
Figure 19, Figure 20, Figure 21, Figure 22, Figure 23 compare the KM survival curves for 
those with or without respiratory comorbidity for Carstairs Deprivation Quintiles 1 through 
5 in ascending order.  The difference in survival remains (in that individuals with 
respiratory illnesses have poorer survival) but the curves are similar for all quintiles with 
no clear difference between the least and most deprived quintiles. 
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Figure 12 - KM plot for females with and without respiratory comorbidity 
 
Figure 13 - KM plot for males with and without respiratory comorbidity 
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Figure 14 - plot for ages  < 55 with and without respiratory comorbidity 
 
 
 
Figure 15 - plot for ages 55-64 with and without respiratory comorbidity 
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Figure 16 - plot for ages 65-74 with and without respiratory comorbidity 
 
 
Figure 17 - plot for ages 75-84 with and without respiratory comorbidity 
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Figure 18 - plot for ages over 85 with and without respiratory comorbidity 
 
 
 
Figure 19 - plot for patients in deprivation category 1 with and without respiratory comorbidity   65 
 
Figure 20 - plot for patients in deprivation category 2 with and without respiratory comorbidity 
 
 
Figure 21 - plot for patients in deprivation category 3 with and without respiratory comorbidity   66 
 
Figure 22 - plot for patients in deprivation category 4 with and without respiratory comorbidity 
 
 
Figure 23 - plot for patients in deprivation category 5 with and without respiratory comorbidity   67 
KM plots by stroke subtype 
 
Figure 24 - plot for cranial infarction stroke subtype with and without respiratory comorbidity 
 
Figure 25 - plot for intracranial haemorrhage stroke subtype with and without respiratory 
comorbidity   68 
 
Figure 26 - plot for subarachnoid haemorrhage stroke subtype with and without respiratory 
comorbidity 
 
Figure 27 - plot for undefined stroke subtype with and without respiratory comorbidity   69 
The preceding four KM curves show survival for the two groups separated by stroke 
subtype.  The survival difference is most striking for subarachnoid haemorrhage with 
median survival for individuals with no respiratory comorbidity at 4543 days (95% CI 
4257 to 4829) and for those with respiratory comorbidity 1627 days (95% CI 909 to 2345).  
The median survival data is tabulated in Table 24.  Table 25 shows the median survival 
and log rank test data by stroke subtype. 
 
      Median survival (days (95% CI)) 
Log rank (by 
respiratory) 
     
All 
Respiratory comorbidity 
      No  Yes 
   All  818 (803 to 833)  851 (835 to 867)  501 (466 to 536)  p < 0.001 
S
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  Male  1051 (1027 to 1075)  1119 (1093 to 1145)  517 (471 to 563)  p < 0.001 
Female  630 (611 to 649)  644 (624 to 664)  490 (436 to 544)  p < 0.001 
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  <55  6870 (6687 to 7053)  6917 (6727 to 7107)  4217 (3574 to 4860)  p < 0.001 
55-64  2662 (2590 to 2734)  2732 (2657 to 2807)  1735 (1525 to 1945)  p < 0.001 
65-74  1162 (1130 to 1194)  1226 (1191 to 1261)  691 (618 to 764)  p < 0.001 
75-84  398 (382 to 414)  413 (396 to 430)  259 (219 to 299)  p < 0.001 
85+  98 (91 to 105)  99 (92 to 106)  85 (64 to 106)  p < 0.001 
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1  808 (772 to 844)  839 (801 to 877)  503 (419 to 587)  p < 0.001 
2  732 (700 to 764)  770 (735 to 805)  384 (307 to 461)  p < 0.001 
3  803 (769 to 837)  834 (798 to 870)  450 (370 to 530)  p < 0.001 
4  798 (765 to 831)  837 (802 to 872)  510 (433 to 587)  p < 0.001 
5  883 (851 to 915)  920 (886 to 954)  597 (526 to 668)  p < 0.001 
Table 24 - Median survival times and log rank tests 
 
The pattern of greatly decreased survival with increasing age is shown clearly here.  For all 
analyses, the survival difference between those with and without respiratory comorbidity is 
significant by the log rank test (p-value <0.001).  The group surviving longest is the under 
55 year olds with no respiratory comorbidity (6917 days (95% CI 6727 to 7107)) and the 
group with the shortest survival is those aged 85 and over (85 days (95% CI 64 to 106)).  
There is again no consistent pattern of differences in survival between least to most 
deprived quintiles.  For the stroke type data in Table 25 - Median survival by stroke type, 
the least survivable stroke is intracranial haemorrhage 155 days (95% CI 116 to 194) and 
the longest survival is seen with subarachnoid haemorrhage 4322 days (95% CI 4054 to 
4610).  Cranial infarction has the second longest survival and “other” or undefined stroke 
type has the third longest.   70 
 
      Median survival (days (95% CI)) 
Log rank (by 
respiratory) 
     
All 
Respiratory comorbidity 
      No  Yes 
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  SAH  4322 (4054 to 4610)  4543 (4257 to 4829)  1627 (909 to 2345)  p < 0.001 
ICH  155 (116 to 194)  157 (115 to 199)  128 (38 to 218)  p < 0.001 
CI  1574 (1541 to 1607)  1646 (1611 to 1681)  1031 (963 to 1099)  p < 0.001 
Other  478 (463 to 493)  499 (483 to 515)  261 (225 to 297)  p < 0.001 
Table 25 - Median survival by stroke type 
 
Cause of death 
All stroke patients 
Table 26 provides the proportions of modes of death for all the stroke patients by sex.  By 
far the most common cause of death certified was stroke itself or the neurological sequelae 
at 56.9% overall.  Cardiovascular death (such as MI) was second most common at 18.2%.  
Pneumonias make up only 4.6% of deaths with chronic respiratory diseases accounting for 
only 1.9%.  Other causes of death contribute only a minor proportion of the total and the 
percentages are very similar between sexes.  These data are illustrated graphically in 
Figure 28. 
 
   Male n (%)  Female  Total 
Cerebrovascular/Neurological  25921  (52.0)  39953  (60.6)  65874  (56.9) 
Cardiovascular  10033  (20.1)  10997  (16.7)  21030  (18.2) 
Other  4084  (8.2)  5476  (8.3)  9560  (8.3) 
Cancer (other)  3647  (7.3)  3404  (5.2)  7051  (6.1) 
Pneumonia  2367  (4.7)  2924  (4.4)  5291  (4.6) 
Cancer (lung)  1527  (3.1)  967  (1.5)  2494  (2.2) 
COPD/Asthma/Bronchiectasis  1249  (2.5)  960  (1.5)  2209  (1.9) 
Other respiratory  560  (1.1)  570  (0.9)  1130  (1.0) 
Infection  264  (0.5)  302  (0.5)  566  (0.5) 
Venous thromboembolism  223  (0.4)  351  (0.5)  574  (0.5) 
Table 26 - primary cause of death in stroke patients 
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Figure 28 - proportion (%) of primary cause of death amongst males and females with stroke 
(cereb/neuro = cerebrovascular/neurovascular, cardio = cardiovascular, COPD etc = COPD, asthma & 
bronchiectasis, VTE = venous thromboembolism 
 
Stroke patients with prior respiratory comorbidity 
Death certification figures for the stroke patients with respiratory comorbidity are shown in 
Table 27 - primary cause of death in stroke patients with respiratory comorbidity.  Stroke 
and neurological sequelae was the most common cause of death for both sexes (44.6% 
males, 51.8% females and 48.1% overall) and cardiovascular causes was the second most 
common cause (19.8% males, 17.6% females and 18.7% overall).  Chronic respiratory 
diseases contribute as the third most common cause of death in this group at 11.7% overall, 
12.9% for men and 10.5% for women.  Pneumonia, cancer, venous thromboembolism, 
infections and other causes contribute only minor percentages.  Figure 29 presents these 
figures as a bar chart. 
 
   Male  Female  Total 
Cerebrovascular/Neurological  1950  (44.6)  2138  (51.8)  4088  (48.1) 
Cardiovascular  865  (19.8)  724  (17.6)  1589  (18.7) 
COPD/Asthma/Bronchiectasis  563  (12.9)  434  (10.5)  997  (11.7) 
Other  285  (6.5)  286  (6.9)  571  (6.7) 
Cancer (other)  248  (5.7)  150  (3.6)  398  (4.7) 
Pneumonia  186  (4.3)  180  (4.4)  366  (4.3) 
Cancer (lung)  186  (4.3)  115  (2.8)  301  (3.5) 
Other respiratory  54  (1.2)  51  (1.2)  105  (1.2) 
Venous thromboembolism  22  (0.5)  22  (0.5)  44  (0.5) 
Infection  16  (0.4)  25  (0.6)  41  (0.5) 
Table 27 - primary cause of death in stroke patients with respiratory comorbidity   72 
 
 
Figure 29 - proportion (%) of primary cause of death amongst males and females with stroke and 
respiratory comorbidity (cereb/neuro = cerebrovascular/neurovascular, cardio = cardiovascular, 
COPD etc = COPD, asthma & bronchiectasis, VTE = venous thromboembolism   73 
6.  DISCUSSION 
Stroke is clearly a common disorder in Scotland and its crude incidence has changed little 
over the period 1985 to 2005.  Comorbidities are also common with one or more being 
present in 58.1% of patients.  COPD and other chronic lower respiratory diseases are also 
highly prevalent in Scotland and responsible for great mortality in their own right.  The 
specific effects of COPD or other respiratory diseases on stroke outcome were not 
examined by any of the studies found in the literature search.  The results of this study 
cannot, therefore, be directly compared to any other. 
Incidence rates 
The male and female crude incidence levels show a relatively small variation from 1985 to 
2005.  There is a small rise until 1993 and a gradual fall in incidence thereafter.  The 
standardised figures however show a rise in incidence until 1992 followed by a gradual 
reduction in incidence until 2005.  In 2005, the standardised incidence rates for both sexes 
are lower than in 1985.  The figures are comparable to those from the Scottish Borders 
Stroke Study
117.  World standardised rates per 100000 in the SBSS were 71 for infarction 
and 8 for haemorrhage, compared with 61.4 to 80.7 from the SMR data.  The rate 
standardised to the Scottish population in the SBSS was 161 per 100000 (compared with 
137 to 169 from SMR data).  It may not be unreasonable to assume that most strokes 
would be admitted to hospital (and thus appear in the SMR database), but this may not 
necessarily be the case.  It is feasible that mild strokes (especially in areas far removed 
from hospitals) may have been managed at home.  It may also be possible that severe or 
imminently fatal strokes may also have been managed at home (for example in a nursing 
home).  With the recommendations of the Stroke Unit Trialists’ Collaboration
118, there 
may have been an increased tendency for stroke patients to be admitted to hospital in the 
second decade of the study period.  It would certainly seem unlikely that there would be a 
decreasing tendency for stroke admissions.  If this is the case, then the reduction in 
standardised figures may be due to improved primary prevention strategies in Scotland.  
Improved recognition of diabetes, hypertension and other cardiovascular risk factors could 
feasibly lead to an improvement in stroke figures.  Over the period studied, there has been 
a large increase in available evidence based guidelines for recognition and management of 
these risk factors.  Primary care practitioners have been encouraged to target these risk 
factors.  Specific reasons for the trends seen in incidence cannot be ascertained from the 
information in this study and can only be speculated upon.   74 
Baseline characteristics 
Sex and age groups 
For both sexes, the age distribution exhibits negative skew in a normal distribution.  This is 
unsurprising given the wealth of data showing age as a strong risk factor for stroke.  The 
skew is stronger for females in that there are many more very elderly females having 
strokes than men.  For instance, in the 75 to 84 years group, there are over 10000 more 
women than men.  Women of course live longer than men in general, which would account 
for this difference.  The median age of women was 5 years older than the men in the group.  
This is comparable to other studies of stroke, the largest age difference being in the 
PISCIS
47 project where the mean female age was 7.3 years older than for males. 
Deprivation categories 
There are a greater number of strokes with each category of increasing deprivation, which 
agrees with other studies documenting this
119-121.  Risk factors, such as tobacco smoking
122 
and poor health in general
123, are known to be more prevalent in more deprived areas 
which likely explains the bulk of this effect.  This gradient effect is very similar for both 
men and women.  Age subgroup analysis also shows this clearly for both sexes under the 
age of 74.  In the older age groups, the effect is less so.  In the 75 to 84 year olds, the effect 
is fairly uniform but over the age of 85 there appears to be a reverse gradient.  There 
appear to be more strokes in the least deprived quintiles and fewer in the most deprived.  
This was also seen in the Avendano paper
120.  The reason for this is not clear, however a 
possible explanation from the Smits
119 paper may also apply to Scotland.  There is a 
possibility of selection bias.  As the deprivation data is derived from postcodes, patients 
from different areas may have a higher or lower chance of being admitted or dying before 
admission.  This could explain the effect.  It is feasible that very elderly patients from 
deprived areas may have more chance of dying from the first stroke and thus not be 
admitted.  Those from less deprived areas may have less comorbidity associated with 
socioeconomic status and survive until admission.  This could lead to an underestimation 
of the true incidence in very deprived, very elderly persons.  Avendano et al suggest a 
survival effect.  This is the theory that individuals in lower socioeconomic groups may die 
younger from other causes leaving only the healthiest to live into old age.  Also, those in 
lower deprivation groups may live longer and thus have a stroke at a very old age causing 
an apparent reversal of the gradient.  Other factors such as race and genetic susceptibility 
may be important but data regarding this is not present in this study and cannot therefore 
be commented upon.   75 
Comorbid conditions 
Well over half of both sexes had at least one comorbid condition at the time of first stroke.  
The commonest occurring were hypertension and ischaemic heart disease.  Hypertension is 
a well known risk factor for stroke and ischaemic heart disease shares risk factors so this is 
not unexpected.  Comorbidity data from studies examined in the literature search are 
broadly comparable to these figures.  Hypertension, however, was more often present at 
over 50%.  The data from the SMR therefore is far lower than might be expected.  Two 
scenarios may explain this.  Either hypertension is truly less prevalent or is less well 
recognized.  The implications from the latter scenario would be under-treatment of an 
important risk factor in this population.  Definitions of hypertension have also changed 
over the study period, so data from the early years may not be directly comparable to the 
later years.  Diabetes and atrial fibrillation are also risk factors in the aetiology of stroke 
and occur commonly in this population.  Heart failure and respiratory disease were the next 
most commonly occurring conditions.  Heart failure also shares risk factors with stroke 
(smoking, hypertension) but the relationship with respiratory disease is not as obvious.  
There is certainly a link between respiratory disease and stroke (as discussed earlier in this 
thesis), but it is far from clear.  These data provides no insight into causative links, but the 
fact that respiratory diseases are fairly common in the stroke population is in itself 
interesting. 
 
Stroke subtype 
The majority of strokes for both sexes fall into the undefined category.  This is far more 
than in other studies.  OCSP reported 5% as unknown pathological type and most (81%) 
were infarction.  The majority of other stroke studies including subtype data have similar 
figures with few unspecified types, few haemorrhages and mostly infarction.  This could 
represent coding inaccuracies where there is no other information other than “stroke” 
present.  Two studies do give similar results.  Brønnum-Hansen
109 et al found unspecified 
stroke in 54.7% and the Copenhagen City Heart Study
124 had a similar proportion of 53%.  
These studies used a register or coded discharge data.  This is likely more akin to the SMR 
data than many of the other papers which often had neurologists or the trial physician 
following up or even examining the cases.  Two scenarios may explain the high proportion 
of unspecified stroke in the SMR data.  There may be a decision not to CT scan a patient 
who is clearly going to die (when the scan would not change management, but would have 
otherwise defined the stroke as infarction or haemorrhage).  Also a patient with mild or 
unclear signs with unclear results on CT scanning may be placed in this category.  This   76 
may have been more likely at the beginning of the study when CT scanners were either 
unavailable in many hospitals or of low resolution due to the technology available.  It is far 
less likely that this would happen in the latter years given widespread availability of 
scanners and the increased resolution.  The majority of these unspecified strokes are likely 
to be ischaemic (which is the next most common category), as demonstrated in most 
studies of stroke subtype.  It would appear that when cases are followed up by experts, the 
number of strokes labeled as “unclassified” decreases. 
Stroke patients with COPD and other chronic lower 
respiratory diseases 
Prevalence 
Respiratory diseases were present in 6.9% of the stroke population studied.  More men 
(7.7%) than women (6.2%) had documented respiratory disease.  A greater proportion of 
men than women are known to be smokers in Scotland
125, which may explain this statistic.  
This is similar to data from other papers from 5.8%
62 to 15.3%
85.  A study of stroke 
admissions in Glasgow
66 reports COPD as a comorbid condition in 10.2%.  This is slighter 
higher than reported in this thesis for the whole of Scotland, especially as asthma and 
bronchiectasis are also included.  This may relate to the very high levels of smoking in the 
Glasgow area
125. 
Sex and age groups 
The mean ages and distribution across the percentiles are very similar for the subgroup 
with respiratory diseases when compared to the main study population.  However, in all 
stroke patients there was a slight difference in age between sexes with women marginally 
older than men.  In the respiratory cohort, this difference is no longer evident.  The reason 
for men in this group being slightly older is unclear.  There are likely to be more smokers 
in this group so it could be postulated that there may be a selection bias.  Smoking and 
respiratory comorbidity may cause an earlier death from cardiac or respiratory causes, 
therefore selecting the “fitter” patients to survive to a later age and then have their stroke.  
As males have more cardiovascular disease than women in general, there may be fewer 
males living long enough to have a stroke, hence the mean age is higher. 
Deprivation categories 
The distribution of numbers of stroke patients with respiratory comorbidity within the 
deprivation categories is very similar to the whole stroke population.  The socioeconomic   77 
gradient does appear to be more striking, however.  For both males and females, there is a 
greater proportion of the cohort in the more deprived Carstairs deprivation quintiles.  This 
may be an effect of smoking which is likely to be more prevalent in the group of 
individuals with respiratory disease and also more prevalent with decreasing 
socioeconomic status. 
Comorbidities 
In general, a greater proportion of the subgroup of patients with respiratory disease has 
each of the listed comorbidities in comparison to the whole population.  The difference is 
most impressive for the vascular comorbidities.  19.3% had heart failure, compared 
with7.7% of the stroke patients.  34.2% had ischaemic heart disease (compared with 17.6%) 
and hypertension is similarly higher.  Although without direct evidence from this study, it 
is probably safe to assume that a larger proportion of this subgroup are smokers than in the 
whole study population.  If this is true, then the well known links between cigarette 
smoking and cardiovascular and cerebrovascular disease could explain the large 
differences between the two groups.  The growing evidence on poor respiratory function as 
a risk factor for atherogenesis and vascular disease (independent of smoking history), as 
detailed earlier in this thesis, may also be an explanation for this observation. 
Stroke subtype 
There are fewer subarachnoid haemorrhages and marginally more ischaemic strokes than 
in the whole group.  When analysed by age group, the respiratory group appears to have 
proportionally more cerebral infarction and “other” strokes within the younger age groups.  
The reason for this is not clear from the data available.  One theory is that, due to the 
higher levels of comorbidity in this group, fewer patients survive to an old age in order to 
have the stroke (by dying from another condition).  This would mean a larger proportion of 
younger individuals left alive to have a stroke.  Alternatively, respiratory disease or an 
associated risk factor (e.g. smoking) may predispose to stroke at a younger age. 
Survival 
Overall 
The survival rates to 30 days and 1 year for Scottish stroke patients are very similar to the 
rates observed in other stroke studies and lie around the middle of these other observed 
rates.  They are most similar to the studies undertaken in Western countries, although 
lower than two American studies (North Carolina
86 had a 30 day survival rate of 95% in   78 
1980 and GCNKSS
95 had 85.3% in 1999).  It is encouraging that these figures are in line 
with those of similar countries.  There is an increase in the crude mortality from 1995 until 
1999.  This could be due to the effect of an ageing population.  There follows a reduction 
in mortality.  When standardized to European or World populations to account for this, 
there is a more modest increase prior to the reduction.  There may be multiple reasons for 
the change.  Numminen et al
106 found a decrease in severity of stroke which may have 
accounted partly for the decrease in mortality.  There has been a decrease in the incidence 
of stroke over the study period.  Truelsen et al
124 also reported that a fall in incidence was 
an important factor.  Stroke care has improved, as has recognition and treatment of risk 
factors.  Treatment of other comorbidities has also improved, which may have helped 
reduce mortality after stroke from other causes.  Barker et al in Portland
72 also saw a 
decline in mortality.  A corresponding fall in the prevalence of hypertensive heart disease 
was also seen.  It was postulated that this equated to better treatment of mutual risk factors 
for stroke and heart disease.  This could also be the case in the Scottish population.  More 
rapid access to hospitals with CT scanners and therefore faster diagnosis and management 
of acute stroke plus the immediate aftercare could also be a reason for improved mortality.  
Howard et al
86 saw in particular an increase in survival from ICH and SAH.   They also 
thought that better control of risk factors was likely a factor but that better diagnosis may 
have led to the inclusion of less severe strokes with a better outcome, thus reducing the 
overall mortality.  Thrombolysis for stroke is a relatively recent addition to most Scottish 
hospitals may be of some influence in these figures, but most likely only in the last few 
years of the study. 
Short term survival 
Short term survival from stroke is poor.  In Scotland, it is similar to figures from other 
studies, in particular those from the Western World.  It is not as high as the survival rates 
in Oxfordshire
105 (81%) but was greater than the rate in Kolkata
100.  This may be due to 
differences in comorbidities or stroke aftercare.  Das et al thought that poor immediate care 
of stroke was responsible for the high case fatality rate in India.  Stroke care in Scotland 
and Oxfordshire are likely to be similar, but better care and stroke units may have been 
introduced earlier in Oxfordshire.  In a review of Scotland’s stroke services, Dennis
126 
states there were very few stroke units around 1993, but the number has greatly increased 
since.  A quarter of all patients were dead at 30 days.  This is worse with increasing age – 
over a third of those aged over 85 were dead at 30 days.  Survival is also consistently 
worse in women than men.  This is in line with findings from other studies.  The gender 
difference is likely due to the higher proportion of women in the older age groups.    79 
Interestingly, there is little variation in mortality across the deprivation quintiles.  This 
would suggest that hospital care is a more important determinant of survival than social 
background. 
 
The type of stroke associated with poorest survival is intracranial haemorrhage.  Those 
with cranial infarction had the most favourable survival rates.  Subarachnoid haemorrhage 
was also associated with a higher survival rate (although still poor at 72.7% for men and 
69.9% for women).  This probably reflects the younger age of these patients who most 
likely had few comorbidities.  These rates are similar to those reported in Perth
55 (60% in 
1990 and 75% in 2001) and the GCNKSS
95 (62.8% in 1994 and 68.7% in 1999).  Many of 
the other studies reviewed had much lower survival rates for SAH (48% in 1969, 
Rochester, 54% in 1981, Framingham and 55% in 1986, Oxfordshire).  These studies were 
all performed much earlier than the data in this paper and are therefore not directly 
comparable.  Diagnosis, treatment and aftercare of SAH have changed over this period.  It 
likely reflects an increased ability to pick up and treat SAH at an earlier stage, thus 
increasing survivability.  Survival rates in Finland
98 over a similar time period are still poor 
(46.2% for SAH in 1991) despite increased treatment of risk factors and improved care.  
The undefined “other” stroke type had a similar survival rate to SAH and CI.  This 
category may incorporate patients with a clinical diagnosis of stroke but vague neurology 
and equivocal CT (most likely infarction), patients arriving in a moribund state where 
further classification is not possible (or helpful clinically) and CT may not be performed 
and patients who may not have had stroke.  The balance is probably toward those with 
mild infarcts as an excess of moribund patients would have put the survival figure closer to 
that of ICH.  Studies with a stringent follow-up of patients such as Oxfordshire
50;105 had a 
much lower survival rate for this category of stroke (26%).  This may mean that milder 
strokes with a more favourable outcome were more accurately diagnosed as infarction.  
Thus the unclassified group would be more likely to consist of moribund patients where 
clinical state may have made accurate diagnosis either more difficult (due to speed of 
decline) or clinically unhelpful (if a patient would be for palliative care in any event). 
Long term survival 
Survival at 1 and 5 years is very poor.  This is again very similar to reports from other 
studies.  The lowest survival was 48% in Moscow
99 and the highest 65.9% in Finland
98.   
Overall, just over half (58.1%) are alive at 1 year and just over a third (35.2%) at 5 years.  
This is again worse in females than males.  The age gradient is much more pronounced 
than at 30 days.  At 1 year 80.2% of under 55 year olds were alive but only 36.6% of the   80 
over 85s.  This means that those under 55 had more than twice the likelihood of being alive 
at 1 year than the over 85s.  At 5 years, the under 55s were more than 6 times likelier to 
survive than the over 85s. Some of this may be explained by better general fitness and less 
comorbidity in the young.  However, the probability of death from any cause must increase 
with increasing age in the general population.  An elderly survivor of first stroke is in 
general less likely than a 55 year old to survive the next 1 or 5 years for a myriad of 
reasons related to age. As at 30 days, there is little variation with survival at 1 and 5 years 
across deprivation categories. 
Survival with comorbid conditions 
Patients with any one or more comorbidities had similar survival rates at 30 days.  At 1 and 
5 years, the two groups diverge so that having any comorbidity is associated with worse 
survival.  It seems logical that having no comorbidity is beneficial to longer term survival.  
Those with diabetes and hypertension had some of the higher 30-day, 1 and 5 year survival 
times.  These are recognized risk factors for vascular disease.  It may be that the treatment 
of these diseases led to less severe strokes.  The converse of this could be that the other 
categories included people with unrecognized and therefore untreated diabetes and 
hypertension, leading to more severe strokes.  Cancer, heart failure and renal failure carried 
the worst survival rates at 30 days, 1 and 5 years.  This is unsurprising given the poor 
outcomes from these diseases in general 
 
The effect of chronic lower respiratory tract diseases on 
survival of stroke patients 
Chronic lower respiratory tract diseases were associated with poorer survival following 
first stroke.  This is still evident when analysis of age groups, deprivation categories and 
stroke subtype is performed.  Women have poorer survival at 30 days, but the difference in 
survival between men and women is less at 1 year and there may even be a tendency for 
greater survival in women at 5 years (although there is some overlapping of confidence 
intervals).  The Kaplan-Meier curves show a rapid divergence in survival with respiratory 
disease consistently associated with a poorer outcome.  This difference is maintained for 
the period of follow up in all subgroup analyses, but is less obvious with increasing age.  
Median survival time is statistically different (log rank (by respiratory) p value < 0.001) for 
all subgroups.  The mean age of males was higher than in the whole study cohort and there 
was no difference in mean age between the sexes (as there was in the whole cohort with 
males being younger).  There are fewer patients in the very young age groups (less than 55   81 
and 55-64) than in the whole study population.  There are also fewer patients in deprivation 
categories 1 and 2.  A large proportion of the respiratory disorders are likely to be COPD.  
It is accepted that the vast majority of people need a 20 pack year smoking history (that is, 
smoking 20 cigarettes a day for 20 years) to develop the disease.  Therefore it is expected 
that fewer people would develop it at a younger age.  Younger age was associated with a 
better outcome in the whole stroke population, so the smaller proportion of younger 
patients in the respiratory subgroup may partly account for an overall poorer survival.  
Also, having fewer individuals in the least deprived socioeconomic groups may have some 
contributions.  The burden of smoking is likely to be greater in poorer socioeconomic class.  
Deprivation and smoking most likely contributes to greater comorbidity in these patients.  
The proportion of ischaemic heart disease, hypertension, heart failure and atrial fibrillation 
is certainly higher in this group.  IHD was present in 19.4% of the whole stroke population, 
but was much higher in the respiratory group at 35.9%.  Analysis of cause of death, 
however, does not show any differences between the whole stroke population and the 
respiratory subgroup.  Cerebrovascular causes primarily lead to death in both groups 
studied, at roughly the same proportions.  There is no increase in the proportion of 
cardiovascular deaths seen in the respiratory group, nor is there a difference in pneumonia 
as a cause of death.  A greater proportion of those in the respiratory group die of 
respiratory causes (11.7%) compared with the whole group (1.9%).  This reflects an 
expected greater morbidity from respiratory causes in people already diagnosed with a 
respiratory condition.  Although this accounts for some of the differences in survival, it is 
still a relatively small proportion of the total deaths and a cerebrovascular cause is by far 
the most common, accounting for nearly half.  There must therefore be other factors 
involved.  The proportions of stroke types in the whole group and the respiratory group are 
similar, but stroke severity cannot be ascertained from this data.  If this group of patients 
had more severe strokes within each category, it could contribute to poorer survival, but 
this is just conjecture and would have to be studied further.  As discussed earlier in this 
thesis, respiratory disease is associated with excess cardiovascular risk and it may be that 
there are an excess of cardiovascular deaths in the respiratory group.  Death from MI, for 
instance, may be fairly sudden and have few signs to enable the certifying doctor to label it 
as such.  If the decedent was known to have had a recent stroke, death may be certified as 
stroke in the absence another obvious cause.  Physician accuracy of determining cause of 
death from stroke
127 or cardiac
128 causes can be unreliable and of varying accuracy.  
Studies have compared death certificate cause of death with autopsy findings and have 
shown substantial differences
129.  The reliability of the documented causes of death cannot 
be confirmed or refuted from the data in this study.  A further investigation into accuracy   82 
of death certification would need to be undertaken.  Data from necropsies would be most 
helpful to ascertain accurate cause of death, but unfortunately postmortem rates were 
falling through the study period and have continued to decline in the United Kingdom
130;131.  
Also of particular interest in examining the age groups, the very young (less than 55) with 
respiratory comorbidity have a median survival time that is 2700 days less than for the 
whole cohort.  This difference is lessened with each increasing age group meaning the 
adverse survival effect is maximal in the under 55s.  This potentially has huge implications.  
If survival in this group is so poor, perhaps extra attention should be paid to primary stroke 
prevention in young patients with respiratory disorders, especially COPD.  Of course all 
patients following stroke should have vigorous attention to secondary prevention, but the 
presence of comorbidities (especially respiratory) should prompt the treating physician to 
be aware that survival is likely to be less favourable.  Thus, extra vigilance regarding 
treatment of cardiovascular risk factors is needed. 
Strengths and weaknesses of the study 
A study of this nature can only suggest a relationship between factors and unfortunately 
cannot ascertain causality.  It would be interesting to know whether the group with 
respiratory disease had worse strokes than the whole cohort.  This would involve 
examining admission data such as the National Institute of Health Stroke Scale (NIHSS).  
This is not feasible for a retrospective study of this size and the data is probably not 
available for many of the cases, especially for data towards the beginning of the study 
period where records may have been destroyed.  A study of different design would have to 
be devised.  Although strokes are reasonably likely to be admitted, milder strokes may not 
have been and TIAs are usually only admitted in certain circumstances.  The data may 
therefore be lacking milder forms of stroke disease, which could affect the analysis.  It may 
be important to know how respiratory comorbidities affect outcomes from milder stroke or 
TIA.  Although main admission diagnosis is known to be fairly accurate
114, secondary 
diagnoses are less so.  Again, this could skew the analysis by omitting for example stable 
or mild forms of respiratory disease.  There are likely to be many individuals with 
unrecognized disease who would therefore not have a respiratory comorbidity recorded.  
This is impossible to quantify.  It would therefore be more accurate to perform a study 
where the lung function of each subject was known (although simple spirometry is also 
inherently variable both demographically speaking and is effort dependent).  Smoking 
status data was not available for this study.  Smoking is a well known risk factor for stroke 
and respiratory disease (COPD) and may have been a very big risk factor for adverse 
outcome.  The respiratory group in the study probably contained more smokers; therefore   83 
the ability to correct for this would have been useful.  Despite these problems, the study 
did involve very large numbers of patients which may have helped increase the power of 
the study and keep the confidence intervals small.  It would not be possible to collect very 
large amounts of data on each individual to suit the needs of every research question in a 
database of this size.  Hopefully, however, a study such as this can help identify areas of 
potential concern for further, more detailed research. 
Conclusions 
 
The incidence of stroke in Scotland has decreased since 1986, although this decrease has 
been more rapid since 1998. 
 
A large proportion of stroke patients have one or other comorbidities. 
 
Standardised mortality rates from stroke have fallen over the period 1995-2005, although 
crude rates have not. 
 
Survival from stroke is poor, especially in the long term. 
 
Survival in stroke patients with a respiratory condition is especially poor when compared 
to all stroke patients. 
 
Survival in individuals with stroke aged less than 55 with a respiratory comorbidity is 
especially poor when compared to all individuals of the same age group. 
 
Patients with respiratory comorbidity are still certified as dying from the same causes as all 
stroke patients, namely a cerebrovascular or cardiovascular cause. 7.  LIST OF REFERENCES 
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 8.  APPENDICES 
Year 
All ages  <55  55-64  65-74  75-84  85+ 
Total  Males  Females  Total  Male  Female  Total  Male  Female  Total  Male  Female  Total  Male  Female  Total  Male  Female 
1986  5111760  2462311  2649449  3814237  1918542  1895695  553951  260621  293330  434861  184430  250431  251916  86255  165661  56795  12463  44332 
1987  5099020  2455403  2643617  3798202  1909765  1888437  548552  258216  290336  437669  186521  251148  254879  87768  167111  59718  13133  46585 
1988  5077440  2444319  2633121  3775862  1897403  1878459  545007  257057  287950  436513  186613  249900  257477  89370  168107  62581  13876  48705 
1989  5078190  2443165  2635025  3772358  1893100  1879258  542486  256233  286253  437374  188181  249193  260125  90915  169210  65847  14736  51111 
1990  5081270  2443865  2637405  3776310  1892806  1883504  540044  255400  284644  437189  189081  248108  260368  91363  169005  67359  15215  52144 
1991  5083330  2444515  2638815  3775995  1890986  1885009  536887  254254  282633  441094  191920  249174  259086  91372  167714  70268  15983  54285 
1992  5085620  2445272  2640348  3776162  1889770  1886392  535665  253947  281718  445444  194316  251128  255857  90503  165354  72492  16736  55756 
1993  5092460  2448419  2644041  3781035  1890794  1890241  536030  254628  281402  451300  197302  253998  249393  88264  161129  74702  17431  57271 
1994  5102210  2453342  2648868  3789126  1893745  1895381  535792  254821  280971  457044  200385  256659  243592  86322  157270  76656  18069  58587 
1995  5103690  2453353  2650337  3786530  1890437  1896093  535129  255067  280062  451264  198712  252552  251269  90110  161159  79498  19027  60471 
1996  5092190  2447020  2645170  3775462  1883207  1892255  531712  253660  278052  447732  197778  249954  256208  92700  163508  81076  19675  61401 
1997  5083340  2442322  2641018  3763038  1875333  1887705  531276  254056  277220  445955  197410  248545  260399  95143  165256  82672  20380  62292 
1998  5077070  2438991  2638079  3747550  1865931  1881619  536941  257313  279628  445484  197891  247593  262317  96489  165828  84778  21367  63411 
1999  5071950  2436535  2635415  3733737  1857221  1876516  543141  260969  282172  444420  198082  246338  264516  98260  166256  86136  22003  64133 
2000  5062940  2431926  2631014  3717226  1846995  1870231  546229  263102  283127  445212  199064  246148  266612  100125  166487  87661  22640  65021 
2001  5064200  2433733  2630467  3705330  1840422  1864908  551689  266601  285088  446642  200495  246147  271745  103167  168578  88794  23048  65746 
2002  5054800  2431805  2622995  3668627  1823172  1845455  573294  277735  295559  448587  201954  246633  276287  105746  170541  88005  23198  64807 
2003  5057400  2434566  2622834  3649719  1813456  1668803  588618  285594  303024  452266  204450  247816  280896  108235  172661  85901  22831  63070 
2004  5078400  2446248  2632152  3648785  1812385  1836400  603061  293181  309880  455076  206596  248480  286232  111073  175159  85246  23013  62233 
2005  5094800  2456109  2638691  3648451  1812217  1836234  613255  298599  314656  456697  208182  248515  285749  111781  85228  90648  25330  65318 
Table 28 - General Register Office for Scotland mid year population estimates 1986-2005 Study  Location (n)  Study type  Period 
Incidence 
Men  Women  Total 
PCSS
55 
Perth, WA  Prospective  1989-90  205  177  191 
647  all ages  1995-6  156  157  157 
      2000-1  124  131  128 
Oyabe
107 
Rural Japan  Prospective  1977-81  605  476    
2068  over 25s  1982-6  455  322    
 
   1987-91  417  329    
OCSP
50 & OXVASC
69 
Oxford 429  Prospective  1981-4  226  228  227 
128  all ages  1986  194  207  201 
262     2002-4  150  174  162 
Rochester
132 
Minnesota  Prospective  1985-9  173  124  147 
454  all ages, CI only 
 
  
 
  
Framingham
84 
Mass. US  Prospective  1950-77  7.6*  6.2*   
1030     1978-89  6.2*  5.8* 
 
      1990-2004  5.3*  5.1*   
GCNKSS
95 
Kentucky  Prospective  1993-4    
 
182 
1954     1999       206 
Auckland
51 
NZ 521  Prospective  1981  162  148  135 
1255     1991  113  124  136 
Kolkata
100 
India  Prospective  2003-5  117.08†  178.01†  145.3† 
247  Questionnaire 
     
  
Matao
133 
Brazil  Prospective  2003-4  136†  80†  108† 
81          
 
137† 
Sicily
70  Italy, 62  Prospective  1999-2002  123‡  185‡  154‡ 
PISCIS
47  Chile, 292  Prospective  2000-2  103.2  86.5  97.4 
Finland
98 
Finland 244  Stroke register  1971-3  108.3  107.4  107.9 (264.4§) 
255 
 
1978-80  91.1  95.2  93.2 (181.0§) 
594     1989-91  201.1  239.6  220.3 (194.7§) 
L'Aguila
134 
Italy  Stroke register  1981-91          
4353 
 
1994-98        292 (259‡) 
Dijon
87 
France  Stroke register  1985-89  130.57‡ (88.16†)  73.18‡ (48.47†)  97.87‡ (65.73†) 
3691 
 
1990-94  134.77‡ (88.45†)  80.24‡ (50.78†)  103.22‡ (66.84†) 
 
   1994-99  109.64‡ (72.85†)  68‡ (44.18†)  85.45‡ (56.29†) 
 
   2000-04  124.45‡ (82.82†)  80.09‡ (53.2†)  99.14‡ (66.04†) 
FINSTROKE
54 
Finland  Stroke register  1983-97        379 
5650              246 
Lund-Orup
57;58 
Sweden  Stroke register  1983-85  214  199  207 (134‡) 
   
1993-95  246  225  235 (158‡) 
456     2001-02  257 (190‡)  203 (104‡)  230 (144‡) 
SBSS
117  Scot, 596  Stroke register  1998-2000        280 
STROMA
56 
Sweden  Stroke register  1989  575appx  320appx    
3621  age 50-79 only  1990  657  400    
FINMONICA
135 
Finland  Stroke register  1983-85  267  150    
11392  25-74yrs only  1990-92  241  129    
Poznan
52 
Poland  Hospital data  1977   
216.6 (154.6
**) 
 
182.2 (95.8
††) 
 
198.3 (121.7
‡‡)     retrospective  1985 
Minneapolis
136 
US 3647  Hospital data  1980 
   
416.8§§ 
4783     2002        358.7§§ 
Quebec
88 
Canada  Hospital  1988  119*** (13†††)  110*** (13†††)    
113046  discharge data  1995  120*** (15†††)  119*** (13†††)    
  
 
2002  85*** (15†††)  85*** (14†††)    
Table 29 - Literature table for studies of stroke incidence
                                                 
* Rates are per 1000 person years 
† Standardised to world population 
‡ Standardised to European population 
§ Standardised to Swedish population 
** Age adjusted rates 
†† Age adjusted rates 
‡‡ Age adjusted rates 
§§ Hospitalisation rate only 
*** Infarcts 
††† Haemorrhages Study  Location (n)  Study type  Period 
% 
men 
Mean age 
↑BP
* 
IHD 
  
DM 
  
Prev MI 
  
PVD 
  
A 
 Fib 
CCF 
   Men  Wom  Total 
ARCOS
83 
Aukland, NZ  Prospective
†  1981-2  49.5 
   
71  47.8  10.9  9 
 
  
 
  
   
1991-2  45 
   
70.6  49.7  15.1  13.7 
 
  
 
  
 
   2002-3  46.9 
   
71.8  56  12  15.9 
 
  
 
  
PCSS
55 
Perth, WA  Prospective  1989-90  53.4        76
‡  59.4  34.7  12             
647 
 
1995-6  49.3 
   
79
*  59.2  32.3  15.5 
 
  
 
  
      2000-1  48.1        77
*  56.8  22.4  19.1             
OCSP & 
OXVASC
69 
Ox., UK 429  Prospective  1981-4  49    
 
72.3  60.9  15.6  10.5  18.2  11.7  9.6    
128 
 
1986  48.4 
   
70.6  56.3  17.2  9.4  10.9  7.8  13.3    
262     2002-4  48.1        73.6  45.7  12.2  9.5  12.6  8.8  16.8    
Rochester
60  Minn., US 454  Prospective  1985-89  41 
   
67-80  72.9  20.7  20.7  11.2 
 
5-33  8.7 
Framingham
84 
Mass. US  Prospective  1950-77  48.1  69  69  69  48 (56)  18 (11)  7 (5)        2 (1)    
1030     1978-89  41.2  73  79 
 
43 (38)  21 (13)  8 (6) 
 
   4 (2)    
 
   1990-2004  41.8  76  81 
 
34 (30)  19 (8)  12 (9)        5 (3)    
GCNKSS
95 
Kentucky, US  Prospective
§  1993-4  43    
 
63  44  10  14             
1954 
 
1999  42.3        61  45  10  16             
Sicily
70 
Italy, 62  Prospective  1999-2002  41.9  71.5  74.6  72.5  62  29  26        12    
 
        
 
                          
PISCIS
47  Chile, 292  Prospective  2000-2  56  61.2  68.5 
 
60 
 
21  9 
 
11  4 
Buenos Aires
96  Argentina 535 
Hospital 
data 
2003-6  54.4 
     
77.1  16.3  17 
   
15.5 
 
Portland
72  Oregon, US 196 
Hospital 
data 
1967-71 
       
24  10  12  13 
 
11  16 
STROMA
56 
Malmo, Sweden 
3621 
Stroke 
Register 
1989 
1990 
54.4 
         
15.7 (4.2) 
13 (5.7)       
Table 30 - Literature table of Stroke studies including comorbidity data – part 1 
                                                 
* Figures as total % or male % (female %) 
† Not all were first strokes 
‡ Median age 
§ Comorbidities from the study population, not the stroke subgroup   97 
 
Study  Location (n)  Study type  Period  % men  Mean age  ↑BP  IHD  DM  Prev MI  PVD  A Fib  CCF  CRF  COPD 
KCSS
77  Kansas, US 236  Prospective  2004  44  70 
 
13  23  14 
   
6 
 
14 
Dijon
87 
France  Stroke register  1985-89 
 
66 (67.8)  65.3 
 
10.4  22.2  12.1  22.9 
     
3691 
 
1990-94 
 
*  61.6 
 
12.6  20.1  9.7  29 
     
   
1994-99 
   
61.9 
 
15.7  25.8  12.9  29 
     
   
2000-04 
 
71 (75.6)  64.1 
 
17.5  17.9  10.2  23.1 
     
PNSR
71  Poland 11107  Stroke register  2000 
 
†  72.1  4.6  12.7  6.3 
 
10.7  7.9 
   
 
‡  61.8  42.4  21.2  9.7 
 
23.1  11.9 
   
 
§  64.3  36.6  20.5  12.7 
 
30.8  20 
   
Barcelona
63  Spain 1840  Stroke register  1986-1997 
   
53.2  14.5  21.4 
 
7.7  29.6  5.8  2.8  6.8 
Barcelona
62  Spain 1473  Stroke register  1986-1995  52 
 
52  13  20 
 
7.8  27  5.7 
 
5.8 
Quebec
88 
Canada  Hospital data  1988 
 
73
**  35-38  11-21  11-20 
 
2-4  5-11  3-9  1-5 
 
113046 
 
1995 
   
42  10-21  10-23 
 
2-4  6-15  2-8  5-6 
 
   
2002 
 
76
†  51-56  22-31  19-27 
 
2-4  18-19  4-8  3-5 
 
North Carolina
86 
US 843  Hospital data  1970-3  46  70
†  51  36  17 
           
786 
 
1979-80  48  70
†  63  54  29 
           
GRI
66  Glasgow, UK 412  Hospital data  2004  49.8  67.9  55.1  35.4  17 
 
4.9 
 
9.2 
 
10.2 
VASt
85  North Carolina, US 1073  Hospital data  1995-7 
 
68.1  58.1  26  36  9.6  5.7  12.7  7.7  1.9  15.3 
Portland
72 
Oregon, US 196 
247 
275 
Hospital data 
1967-71 
   
24  10  12  13 
 
11  16 
   
1974-78  35  14  18  15  16  19 
1981-1984  56  16  15  14  14  20 
Table 31 - literature table of stroke studies including comorbidity data - part 2
                                                 
* Male (female) – remainder of studies have age for both sexes combined 
† Comorbidity data for haemorrhagic stroke follows 
‡ Comorbidity data for ischaemic stroke follows 
§ Comorbidity data for unclassified stroke follows 
** Median age Study  Period  CI  ICH  SAH  Other 
Rochester
101  1955-69  79  10  6  5 
Rochester
137  1945-74  75.4  11.3  5.7  7.6 
Framingham
102  1971-81  75  4  10  3 
Oxfordshire
50  1981-86  81  10  5  5 
Perth
55  1989-90  68.9  12.7  4  14.3 
   1995-96  77.9  10.3  2.3  9.4 
   2000-01  75.4  10.4  6.6  7.7 
N Carolina
86  1970-73  78  14
*  8 
   1979-80  49  8  43 
Copenhagen (MONICA)
109  1982-91  31.7  8  5.7  54.7 
CCHS
124  1977-92  36.2  6.8  4  53 
Finland
98  1972-73  61  17  17  1 
   1978-80  73  11  12  4 
   1989-91  79  12  7  2 
PISCIS
47  2000-02  65  23  5  7 
Table 32 - literature table of stroke studies including data on stroke subtype 
 
 
      30-day Survival 
Study  Period  Overall  Thrombus  Embolic  ICH  SAH  Other 
Auckland
51  1981-91  67.8                
      75.9                
Oyabe
107  1977-81  73.2f 82m
†                
   1982-86  75.5f 85.7m                
   1987-91  80.9f 85.8m                
STROMA
56  1989-98  90.7f 90m                
PISCIS
47  2000-02  76.7  82.2     71.1  60  60.9 
Kolkata
100  2003-05  59.92                
GCNKSS
95  1993-94  86.1  90.6     66  62.8    
   1999  85.3  89.8     62.4  68.7    
Table 33 - Literature table of stroke studies including 30-day survival data
                                                 
* Data for ICH and SAH presented combined 
† Female (f) & male (m) data presented separately       30-day Survival  1-year Survival 
Study  Period  Overall  Thrombus  Embolic  ICH  SAH  Other  Overall  Thrombus  Embolic  ICH  SAH  Other 
Rochester
101  1955-69  72  81 
*   16  48  NA                   
Framingham
102  1971-81  78  85  73  18  54                      
Sicily
70  1999-2002  75.8 
 
       
60.9 
         
Oxfordshire
50;138  1981-86  81  90 
*   48  55  26     69  77  38  52  16 
Perth
55†  1989-90  78.1  91.3 
*   62.5  60  33.3                   
 
1995-96  77.5  85.5     54.5  80  35                   
   2000-01  79.8  86.2     52.6  75  57.1                   
N Carolina
86  1970-73  86  93 
*   32   
‡     49  54   
*  18   
‡    
   1979-80  95  96     70        62  68     55       
Portland
72  1967-71  67                 47                
   1974-78  70                 54                
   1981-85  82                 64                
Moscow
99  1972-74  63                 48                
Copenhagen (MONICA)
109  1982-91  72  79     40  56  40  59                
CCHS
124  1977-92  76.3  91.1     47.6  53.1  75.4  65.2  73.6     42.7  40.8  64.2 
Finland EK
98  1972-73  65.2  77.7     26.8  59.5  61.5  56.6  68.9     19.5  52.4  46.2 
Finland EK  1978-80  70.6  75.5     58.6  54.5  50  60.4  65.4     41.4  54.4  25 
Finland FHA  1989-91  76.7  80.6     69.9  46.2  69.2  65.9  68.2     64.4  46.2  53.8 
Table 34 - literature table of stroke studies including 30-day & 1-year survival data 
                                                 
* Data for thrombotic & embolic stroke combined 
† 28 days rather than 30 days 
‡ Data for ICH & SAH is combined 